Multidimensional Family Therapy (MDFT) for young people in treatment for non-opioid drug abuse: a systematic review . by Filges, Trine et al.
 1 
Colophon 
 
  
Campbell Systematic Reviews 
2015:8 
First published: 02 March, 2015 
Search executed: October, 2014 
 
 
 
 
 
 
 
 
 
Multidimensional Family 
Therapy (MDFT) for Young 
People in Treatment for Non-
opioid Drug Abuse: A 
Systematic Review 
 
Trine Filges, Pernille Skovbo Rasmussen, Ditte Andersen, 
Anne-Marie Klint Jørgensen 
 
 
 
 
 Colophon 
Title  Multidimensional Family Therapy (MDFT) for Young People in Treatment 
for Non-opioid Drug Abuse: A Systematic Review 
Authors  Filges, Trine 
Rasmussen, Pernille Skovbo 
Andersen, Ditte 
Jørgensen, Anne-Marie Klint 
DOI   10.4073/csr.2015.8 
No. of pages  124 
Last updated  December, 2014 
Citation  Multidimensional Family Therapy (MDFT) for Young People in Treatment 
for Non-opioid Drug Abuse: A Systematic Review. Campbell Systematic 
Reviews 2015:8 
10.4073/csr.2015.8 
ISSN  1891-1803 
Copyright  © Filges et al. 
This is an open-access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original author and source 
are credited. 
Contributions  Filges, Rasmussen,  and Andersen contributed to the writing and revising of 
this review. Trine Filges, Krystyna Kowalski, Maia Lindstrøm and Madina 
Saidj contributed to the writing and revising of the protocol. The search 
strategy was developed by Kowalski and Jørgensen.  Filges, Rasmussen, 
Kowalski, and Jørgensen contributed to information retrieval and data 
collection. Invaluable help was given by members of the review team at SFI 
Campbell; the research assistants Pia Vang Hansen, Stine Lian Olsen and 
Anne-Sofie Due Knudsen. 
Filges will be responsible for updating this review as additional evidence 
accumulates and as funding becomes available. 
Support/Funding  SFI Campbell, The Danish National Centre for Social Research, Denmark 
Potential Conflicts 
of Interest 
 The authors have no vested interest in the outcomes of this review, nor any 
incentive to represent findings in a biased manner. 
Corresponding 
author  
 
 Trine Filges 
SFI Campbell  
SFI - The Danish National Centre for Social Research 
Herluf Trollesgade 11 
1052 Copenhagen K 
Denmark 
Telephone: +45 33 09 26 
E-mail: tif@sfi.dk  
 
 
 
  
 Campbell Systematic Reviews 
Editors-in-Chief  Julia Littell, Bryn Mawr College, USA 
Howard White,  3ie, UK 
Editors   
Crime and Justice  David B. Wilson, George Mason University, USA 
Charlotte Gill, George Mason University, USA 
Education  Sandra Wilson, Vanderbilt University, USA 
Social Welfare  Nick Huband, UK 
Geraldine Macdonald, Queen’s University, UK & Cochrane Developmental, 
Psychosocial and Learning Problems Group 
International 
Development 
 Birte Snilstveit, 3ie, UK 
Hugh Waddington, 3ie, UK 
Managing Editor   Karianne Thune Hammerstrøm, The Campbell Collaboration 
Editorial Board   
Crime and Justice  David B. Wilson, George Mason University, USA  
Martin Killias, University of Zurich, Switzerland 
Education  Paul Connolly, Queen's University, UK 
Gary W. Ritter, University of Arkansas, USA 
Social Welfare  Jane Barlow, Warwick University, UK 
Brandy Maynard, St Louis University, MO, USA 
International 
Development 
 Peter Tugwell, University of Ottawa, Canada 
Hugh Waddington, 3ie, UK 
Methods  Ariel Aloe, University of Iowa, USA 
Ian Shemilt, University of Cambridge, UK 
  The Campbell Collaboration (C2) was founded on the principle that 
systematic reviews on the effects of interventions will inform and help 
improve policy and services. C2 offers editorial and methodological support 
to review authors throughout the process of producing a systematic review. A 
number of C2's editors, librarians, methodologists and external peer-
reviewers contribute. 
  The Campbell Collaboration    
P.O. Box 7004 St. Olavs plass 
0130 Oslo, Norway 
www.campbellcollaboration.org 
 
 
 4      The Campbell Collaboration | www.campbellcollaboration.org 
Table of contents 
TABLE OF CONTENTS 4 
KEY MESSAGES 6 
Plain language summary 6 
EXECUTIVE SUMMARY/ABSTRACT 9 
Background 9 
Objectives 9 
Search Strategy 10 
Selection Criteria 10 
Data collection and Analysis 10 
Results 11 
Authors’ Conclusions 12 
1 BACKGROUND 14 
1.1 Description of the condition 14 
1.2 Description of the intervention 17 
1.3 How the intervention might work 23 
1.4 Why it is important to do this review 24 
2 OBJECTIVE OF THE REVIEW 26 
3 METHODS 27 
3.1 Title registration and review protocol 27 
3.2 Criteria for considering studies for this review 27 
3.3 Search methods for identification of studies 30 
3.4 Data collection and analysis 31 
3.5 Data synthesis 35 
4 RESULTS 37 
4.1 Results of the search 37 
4.2 Description of the studies 37 
4.3 Risk of bias in included studies 43 
4.4 Effects of the interventions 46 
5 DISCUSSION 59 
5.1 Summary of the main results 59 
5.2 Overall completeness and applicability of evidence 61 
 5      The Campbell Collaboration | www.campbellcollaboration.org 
5.3 Quality of the evidence 62 
5.4 Potential biases in the review process 63 
5.5 Agreements and disagreements with other studies or reviews 63 
6 AUTHORS’ CONCLUSION 65 
6.1 Implications for practice 65 
6.2 Implications for research 66 
7 ACKNOWLEDGEMENTS 67 
8 REFERENCES 68 
8.1 Included studies 68 
8.2 Excluded studies 70 
8.3 Additional references 71 
9 CHARACTERISTICS OF STUDIES 79 
9.1 Characteristics of included studies 79 
9.2 Characteristics of excluded studies 87 
9.3 Risk of bias of individual studies 87 
10 ADDITIONAL TABLES 104 
10.1 Table of comparisons 104 
11 FIGURES 107 
Flow Chart diagram 107 
APPENDIX 110 
 
 6      The Campbell Collaboration | www.campbellcollaboration.org 
Key messages  
PLAIN LANGUAGE SUMMARY 
This publication is a Campbell Systematic Review of the effect of Multidimensional 
Family Therapy (MDFT) for treating abuse of cannabis, amphetamine, ecstasy or 
cocaine (referred to here as non-opioid drugs) among young people aged 11-21 years. 
The misuse of prescription drugs and the use of ketamine, nitrous oxide and 
inhalants such as glue and petrol are not considered in this review. 
 
Youth drug abuse is a severe problem worldwide and recent reports describe 
ominous trends of youth drug abuse and a lack of effective treatment. This review is 
concerned with drug abuse that is severe enough to warrant treatment. It focuses on 
young people who are receiving MDFT specifically for non-opioid drug abuse. 
 
MDFT is a manual-based, family-oriented treatment, designed to eliminate drug 
abuse and associated problems in young people’s lives. MDFT takes a number of risk 
and protective factors into account; the approach acknowledges that young people’s 
drug abuse is linked to dimensions such as home life, friends, school and community 
(Liddle et al., 2004). MDFT aims to modify multiple domains of functioning by 
intervening with the young person, family members, and other members of the 
young person’s support network (Austin et al., 2005). MDFT is thus based on a 
number of therapeutic alliances, with the young drug abuser, his or her parents and 
other family members, and sometimes with school and juvenile justice officials. 
 
After a rigorous search of the literature, five randomized controlled studies with 
samples of 83-450 participants were identified. Three studies were conducted by 
MDFT program developers, one study was conducted by an independent 
investigator with the program developer as a co-author, and one study was 
conducted by independent investigators. Four studies were performed in the US, 
while the other was performed across five European countries. 
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We used meta-analytic procedures to summarise the available evidence on the 
effects of MDFT in comparison with other interventions on drug abuse, education, 
family functioning, risk behavior and retention in treatment. In this review, we 
interpret a value of the standardised mean difference, SMD=0.20 as a small effect 
size, in line with the general practice (Cohen, 1988). We note, however, the 
possibility that such a value might actually represent a larger effect if it is equivalent 
to a large reduction in the percentage of days a youth uses drugs, but we cannot 
comment further as we were unable to analyse the absolute effect of MDFT given 
that no studies comparing MDFT to no other treatment were available. The findings 
are as follows:  
 
- On drug abuse: Based on the available evidence we conclude that MDFT has 
an effect on drug abuse reduction compared to other treatments, although the 
difference is small.  
- On education: There is insufficient evidence to conclude whether MDFT has 
an effect on education compared to other treatments. 
- On family functioning: There is no available evidence to conclude whether 
MDFT has an effect on family functioning compared to other treatments. 
- On risk behavior and other adverse effects: There is no available evidence to 
conclude whether MDFT has an effect on risk behavior and other adverse 
effects compared to other treatments. 
- On treatment retention: MDFT may result in improved treatment retention in 
young drug abusers compared to other interventions 
The evidence found was limited as only five studies were included, and two studies 
had significant amounts of missing data.  The evidence was very limited in terms of 
the outcomes reported on education, family functioning and risk behavior, and was 
insufficient for firm conclusions to be drawn on the effectiveness of the treatment 
with regard to such outcomes. 
 
There is evidence that MDFT is slightly more effective in treating young people’s drug 
abuse than other treatments; however, the difference is small. Furthermore, none of 
the five included studies could be characterised as a robust RCT with a low risk of bias 
on all assessed domains. One study provided insufficient information on core issues 
for the risk of bias to be assessed and therefore we find reason to question the validity 
of this study.  
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Well-designed, randomized controlled trials within this population are needed. More 
research is also required to identify factors which modify the effect of MDFT and to 
identify which particular youth subgroups may be most likely to respond. 
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Executive summary/Abstract  
BACKGROUND 
Youth drug abuse is a severe problem worldwide, and the use of cannabis, 
amphetamine, ecstasy and cocaine (referred to here as non-opioid drugs) is strongly 
associated with a range of health and social problems. This review focuses on drug 
abuse that is severe enough to warrant treatment. The population of interest is 
young people who are receiving MDFT specifically for non-opioid drug abuse. 
 
MDFT is a manual-based family therapy approach that focuses on individual 
characteristics of the young person, the parents, and other key individuals in the 
young person’s life, as well as on the relational patterns contributing to the drug 
abuse and other problem behaviors. A variety of therapeutic techniques are used to 
improve the young person and the family’s behaviors, attitudes, and functioning 
across the variety of domains. MDFT aims to reorient the young person and his/her 
family towards a more functional developmental trajectory based on key principles 
that include: 1) Individual biological, social, cognitive, personality, interpersonal, 
familial, developmental, and social ecological aspects can all contribute to the 
development, continuation, worsening and chronicity of drug problems; 2) The 
relationships with parent(s), siblings and other family members are fundamental 
domains of assessment and change; 3) Change is multifaceted, multi-determined 
and relates to the youths’ cognitive and psychosocial developmental stages; 4) 
Motivation is not assumed, but is malleable; and motivating the young person and 
his or her family members about treatment participation and change is a 
fundamental therapeutic task; 5) Multiple therapeutic alliances are required to 
create a foundation for change; and 6) Therapist responsibility and attitude is 
fundamental to success (Liddle, 2010). 
 
OBJECTIVES 
The main objectives of this review are to evaluate the current evidence on the effects 
of MDFT on drug abuse reduction for young people (aged 11-21 years) in treatment 
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for non-opioid drug abuse, and if possible to examine moderators of drug abuse 
reduction effects, specifically analysing whether MDFT works better for particular 
types of participants. 
SEARCH STRATEGY  
An extensive search strategy was used to identify qualifying studies.  Searches were 
run in October 2014.  A wide range of electronic bibliographic databases were 
searched along with government and policy databanks, grey literature databases, 
citations in other reviews and the included primary studies, hand searching in 
relevant journals, and Internet searches using Google. We also maintained 
correspondence with researchers in the field of MDFT. No language or date 
restrictions were applied to the searches. 
SELECTION CRITERIA 
To be eligible for inclusion, studies must:  
 
 have involved a manual-based outpatient MDFT drug treatment for young 
people aged 11-21 years enrolled for non-opioid drug abuse; 
 have used experimental, quasi-experimental or non-randomized controlled 
designs;  
 have reported at least one of the following eligible outcome variables:  
abstinence, reduction of drug abuse, family functioning, education or 
vocational involvement, retention, risk behavior or any other adverse effect;  
 not have focused exclusively on treating mental disorders; and  
 have had MDFT as the primary intervention.  
 
DATA COLLECTION AND ANALYSIS 
The literature search yielded a total of 6,519 references, of which 170 studies were 
deemed potentially relevant and retrieved for eligibility determination. Of these, 16 
papers describing five unique studies were included in the final review. Meta-
analysis was used to examine the effects of MDFT on drug usage (measured by both 
frequency and problem severity), on education and on treatment retention. 
 
It was not possible to perform a meta-analysis on family functioning, risk behavior 
or other adverse effects, nor was it possible to assess moderators of drug abuse 
reduction effects, or whether MDFT works better for particular types of participants. 
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RESULTS 
Not all the studies provided data that enabled the calculation of comparable effect 
sizes on the different outcomes. Two studies had two comparison groups with 
different individuals, and we performed separate analyses including the different 
control groups where these two studies provided relevant outcome measures. The 
most conservative effects for the different outcomes are reported in the following. 
All outcomes are measured as decreases; hence a negative effect size favours MDFT. 
 
Meta-analysis of the five included studies showed a small effect (around 30 percent 
of a standard deviation for the different control combinations) of MDFT for 
reduction in youth drug abuse problem severity at 6 months post-intake (SMD=-
0.30 (95% CI -0.53 to -0.07, p=0.01 compared to Cognitive Behavioral Therapy 
(CBT), peer group, treatment as usual (TAU), multifamily educational therapy 
(MEI) and Adolescent Community Reinforcement Approach (ACRA)). 
 
At 12 months post-intake meta-analysis of the five included studies showed a small 
effect (around 20 percent of a standard deviation for the different control 
combinations) of MDFT for reduction in youth drug abuse problem severity (SMD=-
0.23 95% CI -0.39 to -0.06, p=0.007 compared to CBT, peer group, TAU, adolescent 
group therapy (AGT) and ACRA). 
 
Pooled results of the four studies providing data on drug abuse frequency reduction 
favoured MDFT. The effect of MDFT for youth drug abuse frequency reduction was 
small at 6 months post-intake (overall around 20 percent of a standard deviation for 
the different control combinations) (SMD = -0.24; 95% CI -0.43 to -0.06; p=0.01 
compared to CBT, peer group, TAU and MET/CBT5). It was not statistically 
significant at 12 month follow-up compared to CBT, peer group, TAU and 
MET/CBT5/ACRA.  
 
Two studies reported on school grades as an outcome, providing data at 6 months 
post-intake only. Meta-analysis favored MDFT when the controls used in the 
analysis were peer group and MEI (SMD = -0.47; 95% CI -0.92, -0.01; p=0.05).  It 
was not statistically significant when the comparisons used in the analysis were peer 
group and AGT. 
 
We extracted data on retention from all five included studies. Meta-analysis 
favoured MDFT for retention of participants for all the different control 
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combinations (OR = 0.44; 95% CI 0.21 to 0.94; p=0.03 compared to CBT, peer 
group, TAU, AGT and MET/CBT5). Overall the results indicated that retention may 
be positively affected by structured MDFT treatment compared to less structured 
control conditions.   
 
AUTHORS’ CONCLUSIONS  
The available data support the hypothesis that, compared with certain other active 
treatments, MDFT reduces the severity of drug abuse among youth. The treatments 
MDFT was compared against in the included studies were Cognitive Behavioral 
Therapy (CBT), peer group, treatment as usual (TAU), adolescent group therapy 
(AGT)/multifamily educational therapy (MEI) and Motivational Enhancement 
Therapy/Cognitive Behavioral Therapy (MET/CBT5)/Adolescent Community 
reinforcement approach (ACRA). Furthermore, the available data support the 
hypothesis that there is a reduction in the frequency of drug abuse when treating 
young drug abusers with MDFT compared to CBT, peer group, TAU and 
MET/CBT5/ACRA at 6 months post-intake, but the effect is not statistically 
significant 12 months after intake. 
 
The number of studies providing data that allowed calculation of an effect size for 
drug abuse reduction was limited, however, and this should be considered when 
interpreting these results. The conclusions that can be drawn about MDFT as an 
effective treatment for young drug abusers compared to other treatments would be 
more convincing if more studies were available. The pooled effect sizes are small and 
confidence intervals are often close to zero. The statistically significance of the 
pooled results on severity of drug abuse among youth 6 months post-intake is 
sensitive to the removal of studies with methodological weaknesses.   
 
Overall, the results also indicate that retention may be positively affected by 
structured MDFT treatment compared to CBT, peer group, TAU, AGT/MEI and 
MET/CBT5/ ACRA which are all less-structured control conditions. However, the 
results must be interpreted with caution as two studies stand out from the others; 
here the effect sizes are large,  confidence intervals are wide, and the estimated 
between study variation is relatively large. 
 
The main conclusion of this review is that there is insufficient firm evidence of the 
effectiveness of MDFT, especially with regard to moderators of drug abuse reduction 
effects, and whether MDFT works better for particular types of participants. While 
additional research is needed, the review does, however, offer support that MDFT 
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treatment to young non-opioid drug abusers reduce their drug abuse somewhat 
more than CBT, peer group, TAU, AGT/MEI and MET/CBT5/ACRA.  
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1 Background 
1.1  DESCRIPTION OF THE CONDITION 
Youth drug abuse1 of the kind that persists beyond the experimentation phase is a 
severe problem worldwide (United Nations Office on Drugs and Crime (UNODC), 
2010). Abuse of drugs such as cannabis, amphetamine, and cocaine, referred to in 
this review as non-opioids, are strongly associated with a broad range of negative 
health implications such as traffic accidents, sexually transmitted diseases, mental 
problems and suicide as well as social problems including poor academic 
achievement, delinquency and violent behavior (Bonner & van den Bree, 2009; Deas 
& Thomas, 2001;  Essau, 2006; Lynskey & Hall, 2000; Office of National Drug 
Control Policy (ONDCP), 2000; Rowe & Liddle, 2006; Shelton, Taylor, Nordstrom & 
Levin, 2007).  
 
While cannabis, amphetamine, cocaine and other non-opioid drugs remain illegal in 
most countries, surveys indicate widespread prevalence. In the US, 25.5 percent of 
12th-grade students report having used an illicit drug (any kind) within the last 
month (Johnston, O’Malley, Miech, Bachman & Schulenberg, 2014). In Canada, 21 
percent of 15-24 year olds report having used of some kind of illicit drug within the 
last year (Health Canada, 2011). In Australia, seven percent 12-17 year olds report 
using some kind of drug within the last month (White & Smith, 2009). The 
European Monitoring Centre for Drugs and Drug Addiction has found that within 
Europe prevalence differs significantly from country to country but that overall 
around a quarter of Europeans report having used some kind of illicit drug in their 
lifetime (European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
2013). 
 
The prevalence of specific kinds of illicit drug abuse varies significantly, with 
cannabis generally being the most commonly used drug. In the US, 22.7 percent of 
12th-grade students report having used marijuana/hashish (types of cannabis), 4.1 
                                                        
1 In this review, we use the term abuse to refer to the consumption of drugs beyond experimentation and into 
addiction. 
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percent amphetamine, and 1.1 percent cocaine during the last 30 days before the 
National Survey on Drug Use conducted in 2013 (Johnston et al., 2014). The 
European Drug Report of 2013 indicates that 11.7 percent of the 15 to 34 year-olds in 
Europe has used cannabis, 1.3 percent amphetamine, and 1.9 percent used cocaine 
during the last year (EMCDDA, 2013). 
 
Although not all drug users progress to severe drug abuse and dependence, some do 
and therefore warrant treatment (see e.g. Crowley, Macdonald, Whitmore & 
Mikulich, 1998). Individuals that warrant drug treatment are described variously as 
abusers, misusers or as dependent. These specific categorizations are used in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) (American Psychiatric 
Association, 1994, 2000). While DSM-IV is widely used, the International Statistical 
Classification of Diseases and Related Health problems (ICD, now ICD-10) 
developed by the World Health Organisation (WHO) is also in wide use. Differences 
between these rubrics concern both terminology and categorization criteria. For 
example, DSM-IV includes the category ‘abuse’, while ICD-10 explicitly avoids this 
term on the grounds of its ambiguity; harmful use and hazardous use are the 
equivalent terms in WHO usage, but the categories are not identical; and while ICD-
10 uses only physical and mental criteria, DSM-IV also includes social criteria 
(WHO, 2011; Nordegren, 2002). 
 
Research draws attention to the significant gap between the number of young people 
classified as in need of treatment and the number of young people who actually 
receive such treatment (SAMHSA, 2010; National Survey on Drug Use and Health 
(NSDUH), 2007). In the US, for example, 7.2 million young people are classified as 
needing treatment for illicit drug abuse, but only 1.4 million of these actually receive 
treatment at a specialty facility for an illicit drug abuse problem (SAMHSA, 2011).  
The treatment usually provided to young people is delivered in outpatient settings. 
Accordingly, 90 percent of the 89,521 clients under age 18 registered in substance 
abuse treatment in 2012 by SAMHSA were in outpatient treatment, which is the 
same proportion as the total treatment population (SAMHSA, 2013). Equal 
proportions of the clients under age 18 were enrolled in facilities with a primary 
focus on substance abuse treatment and in facilities whose primary focus were 
provision of a mix of mental health and substance abuse treatment services; this 
differs from the total treatment population as youth tend to be treated in dual focus 
facilities more often than adults (SAMHSA, 2013). Cognitive-behavioral therapy and 
motivational interviewing are specific therapeutic approaches that are used to some 
extent by most (respectively 91 and 87 percent) treatment facilities (SAMHSA, 
2013). 
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There is growing public concern about the effectiveness and high cost of available 
treatments for young people, and the high rates of treatment dropout and post-
treatment relapse to drug abuse (Austin, Macgowan & Wagner, 2005; Najavits & 
Weiss, 1994; Stanton & Shadish, 1997). While relapse must be acknowledged as an 
expected part of any treatment process targeting individual drug abuse, efforts 
should be made to make treatment as attractive, accessible and relevant as possible 
for young people in order to minimize the risk of unwarranted dropout and 
continuous relapse (Simmons et al., 2008; National Institute on Drug Abuse 
(NIDA), 2009). Furthermore, the services provided should be empirically supported 
to increase the likelihood that (a) treatment will be successful, and (b) public 
spending supports the interventions that are the most effective.  
 
Researchers point to the fact that many research projects claim to have empirically 
validated different kinds of treatment approaches for young drug abusers (e.g. 
Austin et al., 2005; Rowe & Liddle, 2006; Waldron, Turner & Ozechowski, 2006; 
Williams, Chang & Addiction Centre Adolescent Research Group, 2000). The 
current dilemma in the field of youth substance use treatment is that it is not clear 
what works best and for whom as the research suggests that a number of 
interventions lead to reduced drug abuse (Waldron & Turner, 2008). Treatments 
identified as promising are individually based cognitive and motivational therapies 
including Cognitive Behavioral Therapy, Multisystemic Therapy, and Family 
therapies (Deas & Thomas, 2001; Galanter & Kleber, 2008; Kaminer, 2008; 
Waldron & Turner, 2008).  
 
Family therapy covers a range of different interventions, and is based on different 
manuals and varying theoretical sources such as behavioral and cognitive behavioral 
theory, structural and strategic family theory, and family systems theory (Williams 
et al., 2000; Austin et al., 2005). Family-based interventions for the treatment of 
young drug abusers include Multidimensional Family Therapy, Brief Strategic 
Family Therapy, Functional Family Therapy and Family Behavior Therapy (Waldron 
& Turner, 2008; Austin et al., 2005; Rowe & Liddle, 2006; Alexander & Sexton, 
2002; Waldron et al., 2006; Williams et al., 2000). Some reviews suggest that these 
family-based therapies are superior to individual-based programs in reducing youth 
drug abuse (Williams et al., 2000; Lipsey et al., 2010; Waldron, 1997). 
 
Young people who abuse drugs persistently and to an extent that warrants treatment 
have unique needs due to their particular cognitive and psychosocial developmental 
stage. Recognizing that young people are particularly sensitive to social influences, 
families and peer groups being highly influential, authorities such as the U.S. 
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National Institute on Drug Abuse recommends that youth drug treatments facilitate 
positive parental and peer involvement (Institute on Drug Abuse (NIDA), 2009: 22). 
Moreover, they recommend that other systems in which the youth participates (such 
as schools and athletics) are also integrated into a comprehensive treatment 
approach to meet the unique needs of young drug abusers (ibid. 23). A number of 
studies and reviews show positive results for family therapies in general, but there is 
a need to synthesize individual study results for specific family therapies to 
determine whether and to what extent specific family therapy interventions work for 
young drug abusers (Williams et al., 2000; Austin et al., 2005; Waldron & Turner, 
2008; Kaminer, 2008; Deas & Thomas, 2001). 
 
This review has explored the specific family-based intervention of Multidimensional 
Family Therapy (MDFT) (Liddle, 2002; Liddle et al., 2001; Liddle, Rowe, Dakof, 
Henderson & Greenbaum, 2009) as aggregated evidence for MDFT’s effects is 
needed. The review has attempted to clarify the effects of the MDFT program for 
relevant groups of young people aged 11-21 living with their families, and has 
focused on young people enrolled in treatment for drug abuse, independent of how 
their problem was labeled. Enrolment in drug treatment indicates that the severity 
of the young person’s drug abuse has caused the young person or a significant adult 
close to the young person (such as teacher, parent, social services worker, school 
counselor) to seek treatment. The review focused on MDFT delivered as outpatient 
treatment2 and primarily on non-opioid drug abuse3; it is one in a series of reviews 
on different manual-based family therapy interventions for young people in 
treatment for drug abuse4. 
 
1.2  DESCRIPTION OF THE INTERVENTION 
Multidimensional Family Therapy (MDFT) has evolved over the last twenty years 
and is a manual-based, family-oriented treatment designed to eliminate drug abuse 
and associated problems in young people’s lives (Liddle, 1999; Liddle, 2002; Liddle 
et al., 2009). MDFT is one of several family therapy forms that meet the general 
characteristics of manual-based family therapies in that it deals with young people 
                                                        
2 A Cochrane review has evaluated psychosocial interventions for substance abuse and misuse in young 
offenders in locked facilities (Townsend et al., 2009). 
3 A Cochrane review has evaluated psychosocial treatments for treatment of opioid dependence (Amato et al., 
2009). 
4 Please see the following Title Registrations in the Campbell Library for further information: Lindstrøm et al 
(2011). Family Behavior Therapy (FBT) for young people in treatment for illicit non-opioid drug use; 
Kowalski et al (2011). Functional Family Therapy (FFT) for young people in treatment for illicit non-opioid 
drug use;  Lindstrøm et al (2011). Brief Strategic Family Therapy (BSFT) for young people in treatment for 
illicit non-opioid drug use 
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and their families as a system throughout treatment, and thereby recognizes the 
important role of the family in the development and treatment of young people’s 
drug abuse problems (Liddle et al., 2001; Muck et al., 2001). 
 
MDFT is designed to take into account a number of risk and protective factors, and 
it acknowledges that young people’s drug abuse is linked to multiple dimensions: 
home life, friends, school and community (Liddle et al., 2004). As such it advocates 
that a multi-dimensional approach is needed to resolve the young person’s 
problematic drug abuse, and therefore aims to modify multiple domains of 
functioning by intervening with the young person, family members, and other 
members of the young person’s support network (Austin et al., 2005). This also 
means that MDFT is based on multiple therapeutic alliances; with the young drug-
user, his or her parents and other family members, and perhaps school and juvenile 
justice officials. While some young people have only a single parent and few 
significant others relevant to therapy, others might have two sets of parents and 
many significant others relevant to therapy, and the therapist must organize the 
treatment accordingly. 
 
Treatment focuses on individual characteristics of the young person, their parents, 
and other key individuals in the young person’s life, as well as on the relational 
patterns contributing to the drug abuse and other problem behaviors. A variety of 
therapeutic techniques are used to accomplish this and to improve the young person 
and the family’s behaviors, attitudes, and functioning across the variety of domains 
(Liddle, 1999). MDFT aims to reorient the young person and family toward a more 
functional developmental trajectory on the basis a variety of key principles, 
including: 1) Individual biological, social, cognitive, personality, interpersonal, 
familial, developmental, and social ecological aspects can all contribute to the 
development, continuation, worsening and chronicity of drug problems; 2) The 
relationships with parent(s), siblings and other family members are fundamental 
domains of assessment and change; 3) Change is multifaceted, multi-determined 
and relates to the youths’ cognitive and psychosocial developmental stages; 4) 
Motivation is not assumed, but is malleable and motivating the young person and 
family members about treatment participation and change is a fundamental 
therapeutic task; 5) Multiple therapeutic alliances are required to create a 
foundation for change; and 6) Therapist responsibility and attitude is fundamental 
to success (Liddle, 2010). 
 
MDFT’s theory of change hypothesizes that changing the family system 
constructively will produce changes in youths’ drug abuse (reduction or elimination) 
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as well as improvements in relation to other emotional and behavioral problems 
(Hogue, Liddle, Dauber, & Samoulis, 2004, Liddle et al, 2005). Specifically, MDFT 
process studies have emphasized the importance of addressing cultural themes and 
increasing youths’ participation in treatment (Jackson-Gilford, Liddle, Tejeda & 
Dakof, 2001) and improving parents’ skills (Schmidt, Liddle & Dakof, 1996). 
Moreover, the quality of therapeutic alliances between both the therapist and the 
youth, and the therapist and parent(s) are emphasized as decisive for the production 
of change (Robbins et al. 2006). 
 
1.2.1   Theoretical background 
MDFT combines elements of several theoretical frameworks, including family 
systems theory and developmental psychology (Bronfenbrenner, 1979; Minuchin, 
1985; Stroufe & Rutter, 1984), ecosystems theory and the risk and protective model 
of adolescent substance abuse (Austin et al., 2005; Hogue & Liddle, 1999; Liddle & 
Hogue, 2000). The influence of ecological and developmental theory in MDFT is 
evident as the intervention takes into account the changing environments and 
multidimensional systems in which young drug abusers reside (Liddle, 2002; Liddle 
et al., 2001).  
 
Like other family system-based therapies, MDFT builds upon the assumption that 
families can be viewed as systems with structures, hierarchies and patterns of 
interaction that influence each individual family members’ actions (Poulsen, 2006). 
MDFT views any system of interrelated and interdependent family members as both 
unique and changeable. Problem behavior is understood in relation to the family 
context, and youth deviance (including drug abuse) is associated with maladaptive 
social interaction patterns in the family. Accordingly, MDFT theorizes that 
interventions should be directed at families rather than at individuals. The family, 
however, is itself part of a larger social system, and just as young people are 
influenced by their families, the family is influenced by the larger social (and 
cultural) systems in which they exist (Austin et al., 2005; Doherty & McDaniel, 
2010; Kaminer & Slesnick, 2005; O’Farrell & Fals-Steward, 2008; Poulsen, 2006). 
Family therapies are thus also concerned with the wider social context in which the 
individual and the family are embedded. 
 
The focal areas of MDFT (family, peers, and networks) are each considered to be a 
‘holon’, i.e. they are at the same time viewed as systems on their own and as sub-
components of a larger unity (Bertalaffny, 1976, Bronfenbrenner, 1979). This means 
that a family is viewed as simultaneously a whole (composed by individual family 
members) as well as a “part” of other systems (such as communities) (Liddle, 2002; 
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Minuchin & Fishman, 1981; Koestler, 1978). A therapist’s job is to understand the 
workings of each system or ecology as both a whole and a part, and to devise 
interventions that fit the individual and the systems he/she is part of. For example, 
relationships with parents and/or peers must be included in therapy as part of 
changing problem behavior such as drug abuse. Approaching systems as 
simultaneously wholes and parts is identified as a core element in the MDFT-
intervention (Liddle, 2002). 
 
To produce change, MDFT proposes that therapists should focus on parenting skills 
and family interaction. However, MDFT stresses that this is not necessarily 
sufficient for a change in the young person’s drug abuse. A key idea is that 
therapists, in addition to working with both internal family factors (such as family 
patterns and rituals, perceptions of each other and oneself), also need to address 
external systemic factors (such as peer relations, school and other pro-social 
institutions). Thus, MDFT aims at reducing symptoms and enhancing pro-social and 
normative developmental functions in problem youths, by targeting the family as the 
foundation for intervention and simultaneously facilitating curative processes in 
several domains (systems) of the young persons’ lives. Particular behaviors, 
emotions and thinking patterns related to problem formation and continuation are 
replaced by new behaviors, emotions, and thinking patterns associated with 
appropriate intrapersonal and familial development (Liddle, 2002; Liddle, Cecero, 
Hogue, Dauber & Stambaugh, 2006). 
 
The emphasis on therapists working simultaneously with several systems to produce 
change in young people’s problem behavior is not unique to MDFT. Rather, this is 
generally emphasized in family therapy approaches (Dakof, Godley & Smith 2011). 
Likewise, these approaches in general also instruct therapists to be highly non-
punitive and non-judgmental toward youth and parents and stress that therapists 
should collaborate with youth and parents to develop meaningful, client-driven 
goals (ibid, p. 264). The distinctiveness in MDFT derives from the assembly of 
theories, methods and techniques into specific therapeutic principles that guide the 
intervention step-by-step as outlined in the following section. 
 
1.2.2    MDFT components 
MDFT is manual-based but is flexible with regards to its duration, settings and, to 
some extent, therapeutic methods (Liddle, 2002). It has been developed over time 
and has been used by both experienced family therapists and clinicians with no 
family therapy experience, but ideally (according to the MDFT manual; Liddle, 
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2002), both therapists and supervisors should have a background in family therapy 
and/or child development. 
 
The MDFT approach has been developed and tested since 1985. Since 1991, this 
work has been performed through the Center for Treatment Research on Adolescent 
Drug Abuse, Miami USA. The latest version of the MDFT manual was published in 
2002 (Liddle, 2002). 
 
The comprehensive multidimensional assessment is hypothesized as a key feature in 
the success of MDFT for young people experiencing multiple problems. Assessment 
in MDFT provides a therapeutic map, directing therapists where to intervene in the 
multiple domains of the young person’s life. The process involves not only the 
identification of different problem areas, symptoms, and co-occurring disorders, but 
also risk and protective factors in all relevant domains, so that these factors can be 
targeted for change. Through a series of individual and family interviews, meetings 
with school, court, and other mental health professionals, and observations of family 
interactions, the therapist seeks to answer critical questions about functioning in 
each area. First, assessment is an ongoing process throughout therapy, continually 
integrated with interventions to calibrate treatment planning and solving. Second, 
guided by this multidimensional assessment, the model addresses common root 
factors underlying a range of emotional and behavioral symptoms that co-occur with 
young persons’ drug abuse.  
 
MDFT is organized into phases, based upon knowledge of what is considered to be 
normal cognitive and emotional development for young people. Each phase 
represents one of several targets for assessment, intervention, and change, and the 
therapist will not progress to the next phase until the therapy has completed the 
current phase. 
 
Each phase is implemented through four types of treatment sessions (Liddle, Dakof, 
Turner, Henderson & Greenbaum, 2008; Liddle et al., 2006, Liddle, 2002): 
individual sessions with the young person, sessions with the parent(s), sessions with 
other family members and systems external to the family5 , and sessions to change 
the parent(s)-young persons-interaction(s).  
 
The three phases structuring the MDFT intervention aim to:  
                                                        
5 Sometimes the assessment of component three is split into two: a) a component concerning other family 
members and b) a component concerning systems external to the family, and thereby five components are 
presented in some MDFT studies (Liddle, 2002). 
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1) form therapeutic alliances and build the foundation for therapy;  
2) take action and make changes ; and 
3) seal the changes and guide the family members toward creating a healthy 
internal relationship. 
 
Phase 1: Therapeutic alliances 
Engaging both the young person and his or her family in the process of change is the 
main objective in the first phase of MDFT (Liddle et al., 2001). Engagement 
strategies include the formulation of therapeutic alliances with the youth, family 
members, and other extra familial support systems. Liddle (2002) concludes in the 
MDFT manual that the first phase is important and includes presenting therapy as a 
collaborative process, defining therapeutic goals that are meaningful to each 
participant, generating hope and attending to each participant’s experience. The 
focus is on individualizing treatment for each of the family members involved 
through the development of personal and individualized treatment objectives for 
each participant. The use of culturally specific themes is also cited as a useful tool for 
engaging diverse youths and families (Liddle, 1999).  
 
The first phase will typically last for three weeks and is oriented at motivating and 
preparing the family for therapy, explaining the therapy to the family, and creating 
expectations. During this phase, the therapist will meet people relevant to the 
family. In some cases, it will be relevant to include siblings and relatives, while in 
other cases friends or perhaps a social worker are relevant depending on whom the 
young drug abuser spends most of their time with. The beginning of the first phase is 
crucial and it can be a challenging task to engage the family positively; especially as 
the young person can be resistant, often denies his/her drug abuse, and may lack 
cooperation. The first phase in forming therapeutic alliances allows for the MDFT 
program to be flexible and adaptable to different social settings, family structures 
and cultures (for example, single parents, different ethnic groups) and co-occurring 
conditions (for example, juvenile justice system issues, or co-morbid mental health 
conditions).  
 
Phase 2: Make changes 
In the second phase, the therapist will take action by mobilizing the young person 
and his/her family network, by working with the different systems (school, peers, 
family, community workers), and by the practice and training of the family 
members’ stress and communication handling skills, as well as by preventing or 
preparing for detours. 
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The second phase is more behaviorally focused and includes efforts to increase the 
young person’s pro-social behaviors, positive social networks, and antidrug 
behaviors and attitudes. There is also an emphasis on developmental issues, 
including a focus on increasing developmentally appropriate family interactions. 
Teaching problem-solving and decision-making skills and modifying defeating 
parenting beliefs and behaviors through a process called enactment are the primary 
techniques used by MDFT clinicians during phase two.  
 
The therapist will work with the young person and the parents, both individually 
and together as a family, to observe how they communicate and treat each other. 
The therapist assesses different aspects of the young person’s life and then starts the 
process of change by asking, ‘what are the missing aspects of the young person’s and 
family’s lives? What set of circumstances and what specific day-to-day activities and 
intrapersonal and interpersonal processes could reverse the current development-
threatening circumstances?’ (Liddle, 2002)  
 
Phase 3: Seal the changes and end of therapy 
In the third phase, the therapist will seek to maintain the changes in the behaviors, 
emotions and thinking patterns of the family members. This is also the phase where 
the therapist will prepare for the MDFT sessions to end and works with the young 
person and family to generalize the newly acquired skills and behaviors for future 
situations to maintain the positive changes. MDFT does not include an aftercare 
component. 
1.2.3    Duration and setting  
Within the overall frame of MDFT, the components can be practiced in slightly 
different ways according to the clinical needs of the young person and his or her 
family (Rowe & Liddle, 2003; Liddle, 2002). MDFT has been developed and tested 
in different forms or versions, making it a flexible intervention. For example, an 
intensive outpatient version consists of 25 sessions over six months, and a less 
intensive version consists of 12 sessions over three months (Liddle, 2002). The 
frequency of sessions will depend on the needs of the family. Sessions can take place 
in clinical or home settings. 
 
1.3  HOW THE INTERVENTION MIGHT WORK 
Overall, MDFT proposes to produce positive changes through working 
simultaneously with different systems – inside and outside the family – to end drug 
abuse and related problems (Liddle, 2002; Rowe, 2010). MDFT outlines a three-
phase model that explicates how the intervention is to be administered. Stage 2 is 
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highlighted as the working phase of treatment, where significant change attempts 
are made within and across systems (Liddle et al., 2005). 
 
The working phase of MDFT includes an adolescent module, a parent module and a 
family interaction module. In the adolescent module (Liddle et al., 2005, p. 140-
141), the therapy seeks to produce change through a range of techniques such as 
helping the youth examine positives and negatives about their drug abuse as well as 
helping the youth articulate hopes and dreams for the immediate and long term. 
Overall, the module aims to help the youth see that they will have difficulties in 
achieving the things they say they want as long as current problem behavior 
continues, and the therapist helps the youth create concrete pathways toward a 
change of lifestyle.  
 
In the parent module (Liddle et al., 2005, p. 141-142), the therapy seeks to produce 
change by, for example, clarifying and responding to parents’ needs (e.g. for extra 
psychiatric service), instilling hope that change is possible (e.g. through bringing 
small signs of change to their attention), and advising parents – respectfully, but in 
direct terms - on how to handle challenging situations. Overall, the module aims to 
improve parents’ skills, such as their abilities to practice age-proportionate limit-
setting and to enforce house rules, including defining both sanctions and rewards for 
adherence.  
 
In the family interaction module (Liddle et al., 2005, p. 143), to the therapy seeks to 
produce change through helping families to establish more positive patterns of 
interaction, e.g. improving their communication and conflict resolution skills and 
their understanding of the importance of establishing positive, supportive 
relationships.  
1.4  WHY IT IS IMPORTANT TO DO THIS REVIEW 
Persistent drug abuse among young people is a problem worldwide as it causes a 
range of health problems and social problems. Drug treatment targeting young drug 
abusers is challenging and costly as interventions are often plagued by high dropout 
rates and post-treatment relapse into drug abuse. Research suggests that almost half 
of the young drug abusers who receive drug treatment do not complete that 
treatment (Substance Abuse and Mental Health Services Administration, 2008). 
While relapse must be acknowledged as an expected part of any treatment process 
targeting individual drug abuse, there is a need to identify effective treatments for 
addressing young people’s drug abuse problems in order to minimize unwarranted 
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treatment dropout and continuous post-treatment relapse (Simmons et al. 2008, 
NIDA 2009). Furthermore, the growing interest among policy makers in increasing 
funding for evidence-based interventions is a strong motivation to add to the 
evidence base with a systematic review on a promising treatment for young drug 
abusers.  
 
Previous reviews (Vaughn & Howard, 2004; Waldron & Turner, 2008; Becker & 
Curry, 2008) indicate that MDFT is a promising treatment for young drug abusers. 
However, the only meta-analysis thus far conducted (Waldron & Turner, 2008) 
included MDFT as part of a broad category of family therapy rather than including 
MDFT as a distinct treatment model. In contrast, this review examines the effect of 
MDFT and by aggregating individual studies’ results on MDFT, and so contributes to 
the knowledge about treatment of young drug abusers and their families.  
 
The review informs practice by exploring whether results indicate that MDFT works 
better for some client groups than others based on characteristics such as age, 
gender, minority background, family composition (e.g., single parents), and co-
occurring conditions. As previous reviews (e.g. Waldron & Turner 2008) indicate 
that individual treatment outcomes vary widely within intervention models, it is 
important to investigate who might benefit the most from MDFT. The hypothesis is 
that MDFT is not similarly efficacious for all client groups and the review 
investigates whether it is possible to identify subgroups that benefit more than 
others. 
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2 Objective of the review 
The aim of this review was to evaluate current evidence about the effects of MDFT 
on drug abuse reduction for young people (aged 11-21 years) in treatment for non-
opioid drug abuse. Further objectives of this review were, if possible, to examine the 
moderators of drug abuse reduction effects and to examine if MDFT works better for 
particular groups.  
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3 Methods 
3.1  TITLE REGISTRATION AND REVIEW PROTOCOL  
The title for this systematic review was registered in The Campbell Collaboration on 
28.07.2011. The review protocol was registered on 01.09.2012. Both the title 
registration and the protocol are available at: 
http://www.campbellcollaboration.org/library.php.  
 
3.2  CRITERIA FOR CONSIDERING STUDIES FOR THIS 
REVIEW 
3.2.1    Types of studies   
The study designs eligible for inclusion in the review were:  
 Controlled trials (in which all parts of the study are prospective, i.e. 
recruitment of participants, assessment of baseline, allocation to 
intervention, selection of outcomes and generation of hypotheses, see 
Higgins & Green, 2008): 
o randomized controlled trials (RCTs); 
o QRCTs - quasi-randomized controlled trials (QRCTs), where 
participants are allocated by means such as alternate allocation, 
person’s birth date, the date of the week or month, case number or 
alphabetical order; 
o NRCTs - non-randomized controlled trials (NRCTs), where 
participants are allocated by other actions controlled by the 
researcher such as location difference or time difference.   
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3.2.2 Types of participants 
The population included in this review was young people aged 11-21 years enrolled 
in manual based MDFT drug treatment for non-opioid drug abuse (e.g., cannabis, 
amphetamine, ecstasy or cocaine). 
 
Definitions of young people, and the age at which a person is considered a young 
person and may be entitled to special services such as drug treatment, varies 
internationally (United Nations, 2011). Age group distinctions for young people are 
unclear as the boundaries are fluid and culturally specific (Weller, 2006). 
Furthermore, young people start experimenting with illegal drugs at different ages 
in different countries (Hibell et al., 2009) and the pattern of movement from 
dependence on parents to independent living vary internationally.  In order to 
capture international differences, we have set the age range from 11 to 21 years 
(Danish Youth Council, 2011; Hibell et al., 2009; United Nations, 2011; SAMHSA, 
2010).  
 
We included only interventions delivered in an outpatient setting in order to 
evaluate the effects of MDFT on youths living with their families, since family 
interactions are fundamental to MDFT.  
 
We defined the population as young people referred to or in treatment for using 
non-opioid drugs. No universal international consensus exists on categories which 
should be used when classifying drug abusers, and different assessment tools and 
ways of classifying the severity of drug abuse are applied in different research 
studies (American Psychiatric Association, 2000; World Health Organization 
(WHO), 2011; Nordegren, 2002). We included all participants, regardless of any 
formal drug abuse diagnosis. The main criterion for inclusion was that the young 
person was enrolled to participate in the treatment (i.e. the intervention or a 
comparison condition). Referral to and enrolment in drug abuse treatment suggests 
a level of drug abuse such that a significant other or authority (or the young person 
themselves) has found it necessary to seek treatment.   
3.2.3 Types of interventions 
The review included outpatient manual-based MDFT interventions of any duration 
delivered to young people and their family (see 1.2, Description of the intervention). 
The MDFT interventions were required to be interventions that did not include 
overnight stays in a hospital or other treatment facility.  
 
 29      The Campbell Collaboration | www.campbellcollaboration.org 
We did not include any studies where the young drug abuser had been placed 
outside the family home (e.g. inpatient treatment or incarceration in a locked 
facility); this is because MDFT is a family intervention requiring the active 
participation of the young drug abuser and his or her family with the aim of 
improving family functioning, and the core condition of the program would be 
seriously compromised if the young person was not residing within the family home. 
 
Eligible control and comparison conditions included no intervention, waitlist 
controls and alternative interventions, as we were interested in both absolute and 
relative effects.  Due to ethical considerations and the nature of the problem (i.e., 
young peoples’ drug abuse), we anticipated the likelihood of finding a no treatment 
control group to be small.  
 
3.2.4 Types of outcomes 
The primary outcome of interest to this review was abstinence or reduction of drug 
abuse, as the overall review question is to evaluate current evidence on MDFT’s 
effects on drug abuse reduction for young people in treatment for drug abuse. We 
sought evidence on how to best to reduce or eliminate drug abuse, as here it is drug 
abuse that is understood as the young person’s primary problem.  
Primary outcome(s)  
 Abstinence or reduction of drug abuse as measured by, for example:  
 biochemical test (e.g. urine screen measures for drug abuse),  
 self-reported estimates on drug abuse (e.g. Time-line Follow Back 
interview; Sobell & Sobell, 1992), or 
 psychometric scales (e.g. Addiction Severity Index; McLellan, 
Luborsky, Woody & O’Brien, 1980). 
In addition to the primary outcome of interest, we looked for the following 
secondary outcomes, but did not exclude studies on the basis of whether they 
reported any of these outcomes. 
Secondary outcomes  
 Family functioning (e.g. measured by the Beavers Interactional 
Competence Scale; Beavers & Hampson, 2000). 
 Education or vocational involvement (e.g. measured by grade point 
average, attendance, self-reported or reported by authorities, files, 
registers, or employment record.) 
 Retention (e.g. measured by days in treatment, completion rates and/or 
attrition rates) 
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 Risk behavior, such as crime rates, prostitution (e.g. measured by self-
reports or reports by authorities, administrative files, registers) 
 Other adverse effects (e.g. measured by rates of hospitalization, suicide and 
over-doses).  
3.3  SEARCH METHODS FOR IDENTIFICATION OF STUDIES 
3.3.1 Electronic searches  
The searches were run by one review author (AKJ). Relevant studies 
were identified through electronic searches of bibliographic databases, 
government and policy databanks. No language or date restrictions were 
applied to the searches. 
The following bibliographic databases were searched: 
 
Medline, searched to October, 2014  
Embase, searched to October, 2014 
CINAHL, searched to October, 2014  
Social Science Citation Abstracts, searched to October, 2014  
Science Citation Abstracts, searched to October, 2014   
SocINDEX, searched to October, 2014   
PsycINFO, searched to October, 2014   
Cochrane library, searched to October, 2014    
Bibliotek.dk, searched to October, 2014 
LIBRIS, searched to October, 2014  
BIBSYS, searched to October, 2014  
Social Care Online, searched to October, 2014  
ERIC, searched to October, 2014   
SweMed+, searched to October, 2014  
Criminal Justice Abstracts, searched to October, 2014 
Bibliography of Nordic Criminology, searched to December, 2008 
3.3.2 Search terms 
An example of the search strategy for MEDLINE (Ovid platform) is listed below. 
This strategy was modified for each of the databases searched (see appendix). 
1. MDFT .af. 
2. Multi-dimens* adj1 Famil*.af. 
3. Multidimens* adj1 Famil*.af. 
4. Multi adj1 dimens* adj1 Famil*.af. 
5. 1-4/or 
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3.3.3 Searching other resources 
We checked the reference lists of relevant reviews and of reports of the five included 
primary studies for new leads. We also contacted ten international experts (Gayle 
Dakof, Lori Whitten, Minda Lynch, Kathleen Carroll, Debra Davis, Bernadette 
Christensen, Patricia Chamberlain, Brenna Bry, Henk Rigter and Bethany Kleine) in 
attempt to identify unpublished and on-going studies. Two studies were suggested 
but were rejected because they failed to meet the inclusion criteria. 
3.3.4 Hand search 
The following international journals were hand searched from 2011 to the time of 
review submission: 
 Addiction 
 Journal of Consulting and Clinical Psychology 
 Journal of Substance Abuse Treatment 
 Journal of Clinical and Adolescent Psychology 
 Research on Social Work Practice 
3.3.5 Grey literature  
We made additional searches of Google and Google Scholar and checked the first 
150 hits. European grey literature was searched using OpenGrey 
(http://www.opengrey.eu/). We made copies of relevant documents and recorded 
the exact URL and date of access. We also searched the following sites: The National 
Institute on Drug Abuse (NIDA) http://www.nida.nih.gov/nidahome.htm; The 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
http://www.emcdda.europa.eu/index.cfm; and the Substance Abuse and Mental 
Health Services Administration (SAMHSA) http://www.samhsa.gov/ 
3.4  DATA COLLECTION AND ANALYSIS 
3.4.1     Selection of studies  
One reviewer (MS) and one member of the review team (SLO) independently read 
titles and available abstracts of reports and articles identified in the search to 
exclude reports that were clearly irrelevant. Citations considered relevant by at least 
one reviewer were retrieved in full text versions. If there was insufficient 
information in the title and abstract to judge relevance, the full text was retrieved. 
One review author (PSR) and one member of the review team (SLO) read the full 
text versions to ascertain eligibility based on the selection criteria. Any 
disagreements about eligibility were resolved by discussion and consultation with a 
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third reviewer (KK). Reasons for exclusion have been documented for each study 
retrieved in full text, and stored electronically. The study inclusion screening sheet 
was piloted and adjusted as required by the review authors and used throughout 
screening. The overall search and screening process is illustrated in a flow-diagram, 
see section 11. 
 
3.4.2  Data extraction and management 
One review author (PSR) coded the included studies, and a second reviewer (KK) 
checked the coding.  The coding sheet was piloted on several studies (see the review 
protocol; Rasmussen et al., 2012). Numeric data extraction was carried out by one 
review author (TF) and checked by a member of the review team (ADK).  
Data and information were extracted on: characteristics of participants (e.g. age, 
gender, and drug abuse history), intervention characteristics and control conditions, 
research design, sample size, outcomes and results. Extracted data was stored 
electronically.  
3.4.3 Assessment of risk of bias in included studies 
We assessed the methodological quality of studies using a risk of bias model 
developed by Prof. Barnaby Reeves in association with the Cochrane Non-
Randomized Studies Methods Group (Reeves, Deeks, Higgins, & Wells, 2011) 6. This 
model, an unpublished extension of the existing Cochrane Collaboration’s risk of 
bias tool (Higgins & Green, 2008), covers both risk of bias in RCTs and in NRCTs 
that have a well-defined control group.   
The extended model is organized and follows the same steps as the existing Risk of 
Bias model according to the Cochrane Hand book, chapter 8 (Higgins & Green, 
2008). The extension to the model is explained in the three following points: 
1) The existing Cochrane risk of bias tool needs elaboration when assessing non-
randomized studies because, for non-randomized studies, particular attention must 
be paid to selection bias/risk of confounding. The extended model therefore 
specifically incorporates a formalized and structured approach for the assessment of 
selection bias in non-randomized studies7 by adding an explicit item about 
confounding (Reeves, Deeks, Higgins & Wells, 2011).  
                                                        
6 This risk of bias model was introduced by Prof. Reeves at a workshop on risk of bias in non-randomized studies at 
SFI Campbell, February 2011. The model is developed by the Cochrane Non-Randomized Studies Method Group 
(NRSMG). 
7 The extended model was developed to ensure standardization of guidelines and procedures in the Risk of Bias 
assessment of NRS.  
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2) Another feature of non-randomized studies that make them at greater risk of bias 
compared to RCTs is that RCTs must have a protocol in advance of starting to 
recruit, whereas the protocol requirements for non-randomized studies are less 
consistent. The item concerning selective reporting therefore also requires 
assessment of the extent to which analyses (and potentially other choices) could 
have been manipulated to bias the findings reported, e.g. choice of method of model 
fitting, potential confounders considered/included. In addition the model includes 
two separate yes/no items asking reviewers whether they think the researchers had a 
pre-specified protocol and analysis plan. 
3) Finally the risk of bias assessment is refined, making it possible to discriminate 
between studies with varying degrees of risk. This refinement is achieved with the 
addition of a 5-point scale for certain items (see the following section Risk of bias 
judgment for details).  
The refined assessment is pertinent when thinking of data synthesis as it 
operationalizes the identification of studies (especially in relation to non-
randomized studies) with a very high risk of bias. The refinement increases 
transparency in assessment judgments and provides justification for not including a 
study with a very high risk of bias in the meta-analysis. 
 
Risk of bias judgment items and assessment 
The risk of bias model used in this review is based on 9 items: 
 sequence generation (judged as low risk, high risk or unclear – an NRCT will 
automatically have a high risk of bias on this domain) 
  allocation concealment (judged as low risk, high risk or unclear)  
 confounders (judged on a 5 point scale/unclear - only relevant for non-
randomized studies)  
 blinding (judged on a 5 point scale/unclear)  
 incomplete outcome data (judged on a 5 point scale/unclear)  
 selective outcome reporting (judged on a 5 point scale/unclear)  
 other potential threats to validity (judged on a 5 point scale/unclear ) 
 a priori protocol (judged as yes, no or unclear) 
 a priory analysis plan (judged as yes, no or unclear) 
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The assessment was based on pre-specified questions (see section 9.3). “Yes” 
indicates a low risk, “No” indicates a high risk of bias, and “Unclear” indicates an 
unclear or unknown risk of bias. In the 5 point scale, 1 corresponds to No/Low risk 
of bias (e.g. 1 = a high quality RCT) and 5 corresponds to Yes/High risk of bias (e.g. 
5= too risky, too much bias, i.e. a poor quality study). A judgment of 5 points on any 
of the items assessed translates to a risk of bias so high that the findings would not 
be considered in the data synthesis (because they are more likely to mislead than 
inform). None of the included studies were judged 5 on the risk of bias scale8. 
Assessment 
Reviewers (PSR,KK) independently assessed the risk of bias for each included study 
as described in the previous sections. Disagreements were resolved by discussion 
and consultation with a third reviewer with content and statistical expertise (TF). 
We reported the risk of bias assessment in risk of bias tables for each included study, 
see section 9.3.  
3.4.4 Measures of treatment effect  
Standardized mean differences (SMD) were used as the effect size metric for school 
grades, family functioning, drug abuse problem severity, and drug abuse frequency. 
Hedges g was used for estimating SMDs and the data used for these calculations 
were means, standard deviations and sample size. 
 
Odds ratios were used as the effect size metric for retention, and the data used for 
these calculations were number of events and sample size. Computations were 
carried out with the natural logarithm of the odds ratio. Software used for statistical 
analyses was RevMan 5.0. 
3.4.5 Unit of analysis issues 
Multiple interventions per individual  
We did not find any studies in which individuals received multiple interventions.  
 
Multiple time points 
Data from all follow-up durations reported in the primary studies were recorded. We 
used the time points 6 months post-intake and 12 months post-intake and 
performed separate analyses for these time points. We used the treatment 
termination and 6 month follow up outcome measure in two studies (Liddle, 2001, 
                                                        
8 Although one study scored 5 on the item selective outcome reporting for three out of nine outcomes 
(drug use problem severity, drug use frequency and delinquency as only log transformed means and 
standard deviations were reported for these outcomes). These three outcomes are not included in the 
meta analyses. 
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and Liddle, 2008b) as equivalents to the 6 and 12 months post-randomization time 
points. 
 
Multiple intervention groups 
Two studies (Liddle, 2001; Dennis, 2004) had two comparison groups with different 
individuals. As stated in the protocol, multiple control groups were not pooled. We 
performed separate analyses including the different control groups where these two 
studies provided relevant outcome measures.  
Cluster randomized trials 
No cluster randomized trials were included in this review.  
3.4.6 Dealing with missing data and incomplete data 
We assessed missing data and recorded attrition rates in the included studies. We 
were able to discern reasons for attrition from two of the studies (Liddle, 2009; 
Rigter 2011). None of the studies reported an intention-to-treat analysis, although 
Dennis 2004 provided data for all but two of the participants. 
3.4.7 Assessment of heterogeneity  
Heterogeneity among primary outcome studies was assessed with Chi-squared (Q) 
test, and the I-squared, and τ-squared statistics (Higgins, Thompson, Deeks, & 
Altman, 2003). Any interpretation of the Chi-squared test was made cautiously on 
account of its low statistical power. 
3.4.8 Assessment of publication bias 
Reporting bias refers to both publication bias and selective reporting of outcome 
data and results. We were unable to comment on the possibility of publication bias 
because there were insufficient studies for the construction of funnel plots. Selective 
reporting has been considered in the risk of bias assessment and any concerns 
reported in section 4.3.4.  
3.5  DATA SYNTHESIS 
None of the included studies were coded with 5 on the Risk of Bias 5 point scale 
(described in section 3.4.3), and no study was excluded from the data synthesis on 
this basis.  
 
We did not find any studies comparing MDFT to no treatment or to untreated wait 
list controls, and so were unable to examine the absolute effects of MDFT. Our 
analysis of the relative effects of MDFT was conducted on studies that compared 
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MDFT to other interventions and/or to treatment as usual (TAU). All follow-up 
durations reported in the primary studies were recorded. We performed separate 
analyses at 6 months and at 12 moths post intake. 
 
All analyses were inverse variance weighted using random effects statistical models 
that incorporate both the sampling variance and between study variance 
components into the study level weights.  Random effects weighted mean effect sizes 
were calculated using 95 percent confidence intervals. Graphical displays of effect 
sizes (forest plots) are provided in section 4.4. 
3.5.1 Subgroup analysis, moderator analysis and investigation of 
heterogeneity  
We did not identify sufficient studies to allow any moderator analysis to be 
conducted.  
3.5.2 Sensitivity analysis 
Sensitivity analysis was used to evaluate whether the pooled effect sizes were robust 
across components of risk of bias. We conducted a sensitivity analysis for the 
incomplete outcome data and other bias components of the risk of bias checklists by 
removing studies scoring 4 (see section 3.4.3 for a definition). 
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4 Results  
4.1  RESULTS OF THE SEARCH 
We ran the searches in June 2011 and October 2014. The results are summarised in 
the flow chart on page 107. 
 
We identified 6,519 potential relevant records after excluding duplicates (database 
search, 1,425; grey search, 898; hand search, snowballing and other resources, 
4,196). 
 
All 6,519 records were screened based on title and abstract. Of these, 170 were 
retrieved and screened in full text. One hundred and fifty four records did not fulfil 
the screening criteria and were excluded. One paper from the snowball search was 
included. A total of five unique studies, reported in 16 papers, was included in the 
review. Further details of the included and excluded studies are provided in section 
9. 
 
4.2  DESCRIPTION OF THE STUDIES 
4.2.1 Included studies 
Five studies published in 16 articles between 2001 and 2014 met our inclusion 
criteria. Four were conducted in the US. 
 
Liddle 2009: The first study is a randomized controlled trial on the effects of MDFT 
on low-income, ethnically diverse young people aged 11-15 years who were drug 
abusers. It was performed in The Village South, Inc., a nonprofit community drug 
abuse treatment agency in Miami, Florida. The study was reported in three articles: 
Liddle et al., 2004, published in the Journal of Psychoactive Drugs; Henderson et 
al., 2009, published in the American Journal of Drug and Alcohol Abuse and Liddle 
et al., 2009, published in the Journal of Consulting and Clinical Psychology. We 
refer to this study as Liddle 2009, unless specific results from the other two papers 
are addressed, in which case we will cite as Liddle 2004 or Henderson 2009.  
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Dennis et al. 2004: This   is a randomized controlled trial on the effects of MDFT on 
drug (primarily cannabis) using  young people aged 12-18 years, conducted at two 
different sites in Philadelphia, US9. The study was published as Shelef et al., 2005, in 
the Journal of Consulting and Clinical Psychology, and as Dennis et al. 2004 in the 
Journal of Substance Abuse Treatment with data available in an Appendix. This 
study will be referred to as Dennis 2004.  
 
Liddle et al., 2001 is a randomized controlled trial on the effects of MDFT on drug 
using 13-18 year-olds, conducted in the US at an unspecified location. This study 
was published in the American Journal of Drug and Alcohol Abuse and will be 
referred to as Liddle 2001.  
 
Liddle et al., 2008 is a randomized controlled trial on the effects of MDFT on drug 
using 13-17-year-olds who were primarily African American and from low-income 
families. The study was conducted in the Northeast United States, at unspecified 
locations, and was published in four articles: Henderson et al., 2010, in the Journal 
of Consulting and Clinical Psychology;  Hogue et al., 2006, in the Journal of Family 
Psychology; Hogue et al., 2008, in the Journal of Consulting and Clinical Psychology 
and Liddle et al., 2008, in Addiction.  This study will be referred to as Liddle 2008. 
 
Rigter et al., 2011 is a randomized controlled trial on the effects of MDFT on 13-18-
year-olds with a cannabis use disorder. The study (also termed the INCANT trial) 
was conducted in five European countries: Germany, France, the Netherlands, 
Belgium, and Switzerland and the project leader and CTRADA staff from Miami 
visited the nominated centers in each country. They then selected the following 
centers: the department of psychiatry of Brugmann University Hospital in Brussels; 
Therapieladen in Berlin; Centre Emergence in Paris with suburban CEDAT (Conseils 
Aide et Action contre le Toximanie) sub-sites in Mantes la Jolie and St Germain en 
Laye; and the twinning sites of Parnassia Brijder (Mistral, youth addiction care) and 
De Jutters (Palmhuis, youth forensic care) in The Hague. All these sites did well in 
the pilot study and joined the INCANT trial. In Switzerland, the pilot study sites in 
Zurich, Basle and Bern were replaced by Phénix (Geneva) for the actual trial, as the 
potential for recruiting substance abusing adolescents was better there.  This study 
was published in four articles: Rigter et al., 2013, in Drug and Alcohol Dependence, 
Phan et al., 2011, in BMC Psychiatry, Schaub et al., 2014 in BMC Psychiatry and 
                                                        
9 The study refers to four different sites, due to there being two trials in the study, but only one of the 
trials concerns MDFT; it is this that is reported here and concerns two different sites in Philadelphia. 
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Rigter et al., 2011, published online in June 2011 ( [http://incant.eu]. Rotterdam: 
Erasmus MC, Department of Public Health), and will be referred to as Rigter 2011. 
 
Design 
All included studies were described by investigators as randomized controlled trials. 
Three employed a block randomized design (Dennis 2004; Liddle 2008; Rigter 
2011), one study allocated participants using an urn procedure (Liddle 2009); and 
one study did not report the randomization procedure (Liddle 2001). 
Dennis 2004 used block randomization stratified on site (random allocation rule 
equivalent to one block). Dennis 2004 did not specify allocation ratio but it was 
probably 1:1 and did not specify the block size (s). Liddle 2008 used block size of 4 
with allocation ratio 1:1. Rigter 2011 stratified on three or four variables (age, 
gender, level of drug abuse, ethnicity) and used block randomisation with randomly 
permuted blocks of 2 or 4 cases and an allocation ratio of 1:1. Liddle 2009 conducted 
random assignment using a balancing procedure to ensure equivalence of the groups 
on four key variables: gender, age, ethnicity and family income. No further details of 
the urn procedure were reported. 
  
Two studies involved three arms (Dennis 2004 and Liddle 2001); the remaining 
three were, for the purpose of this review, two-armed intervention studies (Dennis 
2004 described two trials, but only one trial dealing with three arms was relevant for 
this review). 
 
Sample size 
Overall, sample sizes were relatively large, with the number of participants 
randomised ranging from 83 (Liddle 2009) to 450 (Rigter 2011). The remaining 
studies comprised 182 (Liddle 2001), 224 (Liddle 2008), and 300 participants 
(Dennis 2004).  
 
Participants 
All five studies focused on the effects of manual-based MDFT for young people with 
substance abuse or dependence, mainly cannabis. Participants included in the 
review ranged from 11 to 18 year, with mean ages ranging from 13.7 to 16.3 years of 
age. 
 
All investigators supplied data on gender and, with the exception of Rigter 2011, on 
family position. Three studies stated explicitly that an inclusion criterion was 
participants living with at least one parent (Liddle 2009, Liddle 2008, and Rigter 
2011). Most participants included within the review were male, comprising between 
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73 to 83 per cent of the study populations in the primary studies. Approximately half 
of the participants were living in single parent households; these ranged from 48 to 
58 percent of the study populations in the primary studies.  
 
Table 4.2.1 Participant characteristics 
 Liddle, 2001 Liddle, 2008 Liddle, 2009 Dennis, 2004 Rigter, 2011 
Age range 
(Mean) 
13-18 (15.9) 12-17.5 (15.4) 11-15 (13.73) 12-18 (-) 13-18 (16.3) 
Gender, males 80% 81% 73% 81% 86% 
Single parent   
households 
48% 58% 53% 55% - 
Two parent 
households 
31% 17% - - - 
White 51% 18% 3% 49% - 
Hispanic 15% 10% 42% 2% - 
Black 18% 72% 38& 47% - 
Other ethnicity  16% 0 15%  2% 40% 
Main drug used Cannabis 
(49%) and 
polydrug use 
(51%) 
Cannabis - Cannabis Cannabis 
 
Intervention characteristics 
All studies included outpatient manual-based MDFT intervention. The average 
duration ranged from 3-4 months (Dennis 2004 and Liddle 2009) to 6 months 
(Rigter 2011). The average number of sessions was 12-15 in Dennis 2004, 16-24 in 
Liddle 2001 and Liddle 2008, 24-32 in Liddle 2009 and 48 in Rigter 2011. 
 
Comparison conditions 
The three two-armed intervention studies (Liddle 2009, Liddle 2008 and Rigter 
2011) all compared MDFT to CBT or CBT-informed interventions that were either 
individual or group-based. In Rigter 2011 the comparison treatments varied between 
the five participating countries, but had elements in common: predominantly CBT in 
Belgium and the Netherlands, psychodynamic approaches were included in France 
and Switzerland, and elements of both these pairs in Germany. 
 
Duration and number of sessions was the same as for the MDFT in Liddle 2009 and 
Liddle 2008. In Rigter 2011 duration was the same as for MDFT, but the number of 
sessions was less than MDFT in all countries except Germany.  In Dennis 2004, one 
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comparison intervention was CBT-informed individual therapy but with a duration 
and number of sessions that was less than MDFT. The duration and number of 
sessions of the second comparison, Adolescent Community Reinforcement 
Approach (ACRA), was the same as MDFT, and four of the sessions included 
parents.  In Liddle 2001, both comparison interventions were of the same duration 
as MDFT, involved the same number of sessions as MDFT and had a varying 
number of sessions including parents. The two comparison interventions were 
multifamily educational therapy (MEI) and adolescent group therapy (AGT). 
 
Outcome measures 
Outcomes measures included self-reported drug abuse and drug problem severity 
assessed via standardized measures: the Global Appraisal of Individual Needs, the 
Personal Experience Inventory and the Problem Oriented Screening Instrument for 
Teenagers.  
 
One study, Liddle 2001, reported using a drug abuse classification scheme as the 
only measure of drug abuse reduction. Adolescent self-report, collateral reports 
(from parents), and urinalysis data were gathered for each adolescent. Information 
from these three data sources were assessed by three experienced clinician-raters 
and used to classify drug abuse consumption on a 15-point scale by the clinician-
raters. 
 
Two studies (Dennis 2004 and Liddle 2001) reported utilizing objective (urine 
samples) and collateral verification (parent report), of drug abuse. 
 
Few secondary outcomes were reported. Education, measured by grade point 
averages and family functioning assessed via self-report and research assistant 
reports were provided in Liddle 2001 and Liddle 2009. Rigter 2011 reported 
adolescent self-reported family conflict and cohesion assessed via standardized 
measures. Delinquency data were provided by Liddle 2009, which were not included 
in the analysis for the reasons explained below. Rigter 2011, provided data on both 
self-reported and parent-reported externalizing symptoms assessed via standardized 
measures.   
 
Regarding retention rates, the studies differed in the types of data they reported 
(completion rates and/or attrition rates, see section 9.1). We used the information 
reported in the five studies that came closest to the proportion of cases with fully 
completed treatment. As not all studies reported proportion of cases with 100% 
completion, the retention rate used for the individual studies varies between 50% 
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and full completion. It is therefore possible to interpret only the difference between 
treatment and control groups; the level of retention could not be compared between 
studies.  The numbers used for calculating retention rates are given in table 4.2.2. 
 
Table 4.2.2  
Study MDFT Comparison 
 Completing1  
(Numbers/%) 
Total number 
randomised 
Completing1  
(Numbers/%) 
Total number 
randomised 
Dennis, 2004. 
MET/CBT5 
70/70% 100 60/60% 100 
Dennis, 2004. 
ACRA 
70/70% 100 61/61% 100 
Liddle, 2001. AGT 33/58% 57 28/44% 63 
Liddle, 2001. MEI 33/58% 57 34/55% 62 
Liddle, 2008. CBT 56/50% 112 56/50% 112 
Liddle, 2009. Peer 
group 
39/100% 40 35/81% 43 
Rigter, 2011. TAU 197/93% 212 165/69% 238 
 
Note 1: Completion varies across the individual studies with some reporting 50% completion 
of the planned dose of treatment and others reporting 100% completion of the planned dose 
of treatment. 
 
Duration of follow-up observations 
The outcomes were reported at varying time points. In three of the studies, 
termination, 6 month follow-up and 12 month follow-up data were available (Liddle 
2001, Liddle 2008, and Liddle 2009). Dennis 2004 and Rigter 2011 provided 3, 6, 9 
and 12 months post-intake data. 
 
Independence 
Three studies were conducted by MDFT program developers (Liddle 2001, Liddle 
2008 and Liddle 2009); one study was ‘semi-independent’ (conducted by an 
independent investigator with the program developer as co-author, Dennis 2004); 
and one study was conducted by independent investigators (Rigter 2011). 
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4.2.2 Excluded studies 
Many studies which appeared (by title or abstract) to be eligible did not ultimately 
meet our inclusion criteria. Some studies were excluded for more than one reason. 
Primary reasons for exclusion are listed below.  
 
Reasons for exclusion  
One study (Becker & Liddle, 2001) was a case study, focusing on single mothers. 
Diamond, Liddle, Hogue, & Dakof, 1999, was a process study focusing on alliance –
building. The outcomes of a prevention study were reported in Hogue et al, 2002. In 
Hogue et al, 1998, the focus was on treatment adherence; and the analysis was 
extended in Hogue et al, 2004. A multicomponent, multi-level technology transfer 
intervention developed to train staff was tested in Liddle, Rowe, Gonzalez, 
Henderson, Dakof & Greenbaum, 2001. 
 
For further details on excluded studies, please see section 9.2, Characteristics of 
excluded studies. 
 
4.3  RISK OF BIAS IN INCLUDED STUDIES 
Overall, the included studies varied on risk of bias judgments and no single study 
could be characterised as a robust RCT with low risk of bias on all assessed risk of 
bias items.  
 
The ratings of each study in relation to the nine domains in the Risk of Bias tool are 
listed below and summarized in Table 4.1 (see also section 3.4.3). The risk of bias 
judgments are based on pre-specified questions and a 5 point scale with ratings of 
1=low risk and 5=high risk. Further details on risk of bias are provided in section 
9.3, Risk of bias for individual included studies. 
 
4.3.1 Allocation    
All five included studies were randomized controlled trials. The methods of 
randomization were described in four studies (Rigter 2011, Liddle 2008, Dennis 
2004 and Liddle 2009) and the method used for sequence generation was judged 
adequate in each case. Concerning allocation concealment, only one study 
mentioned the method used to achieve this (Dennis 2004), and one study simply 
stated that the allocation was concealed (Rigter 2011). It was not possible to judge 
whether concealment of allocation was adequate in the three remaining studies. 
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4.3.2 Blinding  
As is common in social intervention, it is generally impossible to blind participants 
or those delivering the interventions. Only two studies clearly stated that outcome 
assessors were blinded to allocation status (Liddle 2001 and Liddle 2009). 
4.3.3 Incomplete outcome data 
Two studies had very low levels of missing data (Dennis 2004 and Liddle 2009), and 
two studies had relatively high levels (Liddle 2001 and Liddle 2008). All except one 
study (Liddle 2001) dealt with missing data, typically using latent growth curve 
modelling (however, the estimates of the latent growth curve models are not 
included in the meta-analyses in this review). Only one study (Dennis 2004) 
imputed missing data (see section 9.3). 
4.3.4 Selective reporting 
All studies reported data on the primary outcome reduction of substance abuse. 
Although Liddle 2009 did not provide data that enabled the calculation of effect 
sizes because only means and standard deviations of the natural log transformed 
variables were provided, the non-transformed data were kindly provided by 
Professor Howard Liddle. Two studies did not report all the secondary outcomes as 
planned in the protocol (Dennis 2004 and Rigter 2011). We could not locate a 
protocol for the remaining three studies. 
4.3.5 A priori protocol and analysis plan 
We were able to locate a protocol and an a priori analysis plan for two studies 
(Dennis 2004 and Rigter 2011). 
4.3.6 Other potential sources of bias 
The predictability of treatment assignment is an issue for all constrained 
randomization algorithms. This is particularly the case when blocked randomization 
or an urn procedure is used, and when the assignments are revealed subsequent to 
the person recruiting into the trial, it is sometimes possible to predict a future 
assignment, which implies a risk of bias10 (Higgins & Green, 2008; Lachin, Matts & 
Wei, 1988; Berger, 2005). Consequently, none of the studies were rated 1 (low risk of 
bias) on this domain; Dennis 2004, Liddle 2008 and Rigter 2011 because block 
randomization was used, Liddle 2009 because an urn procedure was used, and 
                                                        
10 There is a risk of first-order selection bias when participants or others select the treatment 
assignment which is eliminated with randomization. There is a risk of second-order selection bias when 
upcoming assignments can be observed which is eliminated/minimized by allocation concealment. 
There is risk of third-order selection bias if upcoming assignments can be predicted or even 
determined, if some of the previous allocations are known, and if restrictions are placed on the 
randomization. The third-order selection bias can be controlled by perfect masking. 
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Liddle 2001 because the randomisation procedure was not described. Confounding 
was not relevant in the review since we did not find any NRCTs meeting the 
inclusion criteria. 
 
Table 4.1: Risk of bias assessment 
 Rigter 
2011 
Liddle  
2001 
Liddle 
2008 
Dennis 
2004 
Liddle 2009 
Sequence generation Low  Unclear Low Low Low 
Allocation concealment Low  Unclear Unclear Low Unclear 
Blinding outcome assessors      
Primary  outcome:  abstinence or 
reduction of substance abuse  
 3 1 Unclear Unclear 1 
Secondary outcome: Substance use 
related problems  
 3 Unclear Unclear Unclear 1 
Confounders: Not applicable       
Incomplete outcome data      
Primary  outcome: abstinence or 
reduction of substance abuse 
3  4 4 1 1 
Secondary outcome: Substance use 
related problems and retention 
3   4 n/a 1 1 
Free of selective reporting      
Primary  outcome:  abstinence or 
reduction of substance abuse  
 1  1 1 1 1 
Secondary outcome: Substance use 
related problems  
 4  2 n/a 4 1 
Secondary outcome: Retention   1  2  3  1  Unclear 
A priori protocol Yes   Unclear Unclear Yes Unclear 
A priori analysis plan  Yes  Unclear Unclear Yes Unclear 
Free of other bias 4   Unclear 4 3 2 
The RoB tool is provided in Section 12.3 and the detailed RoB assessment is given in Section 
9.3. In the 5 point scale, 1 corresponds to Low risk of bias and 5 corresponds  to High risk of 
bias.   
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4.4  EFFECTS OF THE INTERVENTIONS 
MDFT was compared to other interventions in all the included studies, and so we 
were only able to analyse the relative effects of MDFT. Two studies, Liddle 2001, and 
Dennis 2004, had two comparison groups with different individuals, and we 
performed separate analyses including the different control groups where these two 
studies provided relevant outcome measures.  
 
In Dennis 2004 one comparison intervention was CBT-informed individual therapy 
(MET/CBT5) and the second comparison was Adolescent Community 
Reinforcement Approach (ACRA).  In Liddle 2001, the two comparison 
interventions were multifamily educational therapy (MEI) and adolescent group 
therapy (AGT). 
 
Throughout this review, we have labelled the analyses (where relevant) as follows:  
1A: 1 refers to AGT used as comparison in Liddle 2001 and A refers to MET/CBT5 
used as comparison in Dennis 2004  
1B: 1 refers to AGT used as comparison in Liddle 2001 and B refers to ACRA used as 
comparison in Dennis 2004  
2A: 2 refers to MEI used as comparison in Liddle 2001 and A refers to MET/CBT5 
used as comparison in Dennis 2004  
2B: 2 refers to MEI used as comparison in Liddle 2001 and B refers to ACRA used as 
comparison in Dennis 2004 
 
Liddle 2001 provided data that enabled the calculation of effect sizes for drug abuse 
problem severity, school grades, and retention. Dennis 2004 provided data that 
enabled the calculation of effects sizes for drug abuse problem severity, drug abuse 
frequency and retention.  
 
The outcomes were reported at varying time points. We grouped the outcomes at 6 
and 12 months post-randomization, using the termination and 6 month follow up 
outcome measure time point in Liddle 2001 and Liddle 2008 as equivalent to the 6 
and 12 months post-randomization time points. 
 
A summary of results is presented in the Table of comparisons, section 10.1, and 
forest plots are displayed in figures 4.1-4.22. The captions below the figures show 
whether results favour MDFT or the control group, and we will concentrate on the 
direction of effects in the text below. 
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4.4.1 Primary outcome results 
It was possible to measure reduction of drug abuse by drug abuse frequency 
reduction as well as by reduction in drug abuse problem severity. One study, Liddle 
2001, provided a drug abuse classification scheme as the only measure of drug abuse 
reduction. We judged that the drug abuse classification scheme compared best with 
the measures of drug abuse problem severity provided in the other studies.  
 
All five studies thus provided data that enabled the calculation of comparable effect 
sizes on drug abuse problem severity reduction, while four studies provided data 
that enabled the calculation of comparable effect sizes on drug abuse frequency 
reduction. Drug abuse frequency and problem severity reduction are measured as 
decreases; hence a negative effect size favours MDFT. 
 
Drug use problem severity 6 months post-intake 
Three studies found statistically significant differences between treatments, all 
favouring MDFT (Liddle 2001, Liddle 2008 and Liddle 2009). In two studies there 
was no evidence of a statistically significant difference between treatments (Rigter 
2011, and Dennis 2004). Pooled results showed a statistically significant effect of 
MDFT for drug abuse problem severity reduction. The random effects weighted 
standardised mean difference (SMD) for analysis 1A was -0.35 (95% CI -0.59 to -
0.11, p=0.004), for analysis 1B SMD=-0.33 (95% CI -0.59 to -0.08, p=0.01), for 
analysis 2A SMD=-0.31 (95% CI -0.53 to -0.10, p=0.004) and for analysis 2B SMD=-
0.30 (95% CI -0.53 to -0.07, p=0.01). There was a statistically significant 
heterogeneity of effects between studies in analysis 1A (τ2=0.04, Q= 10.12, df=4, 
p=0.04), analysis 1B (τ2=0.05, Q= 11.67, df=4, p=0.02) and analysis 2B (τ2=0.04, 
Q= 9.64, df=4, p=0.05). In analysis 2A there was no statistical significant 
heterogeneity (τ2=0.03, Q= 8.18, df=4, p=0.09). The forest plots are displayed in 
Figure 4.1-Figure4.4. 
 
Figure 4.1: Drug abuse problem severity. 6 months post-intake 1A 
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Figure 4.2: Drug abuse problem severity. 6 months post-intake 1B 
 
 
 
Figure 4.3: Drug abuse problem severity. 6 months post-intake 2A 
 
 
 
Figure 4.4: Drug abuse problem severity. 6 months post-intake 2B 
 
 
 
Drug abuse problem severity 12 months post-intake 
Two studies, Rigter 2011 and Liddle 2009, found a statistically significant difference 
between treatments, favouring MDFT, whereas in Dennis 2004, Liddle 2001, and 
Liddle 2008, the effect was not statistically significant. Rigter 2011 found an effect 
on drug abuse problem severity at 12 months, but not at 6 months; we have no 
explanation for this anomalous result. 
 
Pooled results showed a statistically significant effect of MDFT for drug abuse 
problem severity reduction. The random effects weighted standardised mean 
difference (SMD) for analysis 1A was -0.25 (95% CI -0.39 to -0.10, p=0.0007), for 
analysis 1B SMD=-0.23 (95% CI -0.39 to -0.06, p=0.007), for analysis 2A SMD=-
0.27 (95% CI -0.43 to -0.11, p=0.001) and for analysis 2B SMD=-0.25 (95% CI -0.43 
to -0.07, p=0.007). Heterogeneity of effects among studies was not statistically 
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significant in analysis 1A (τ2=0.00, Q= 4.19, df=4, p=0.38), analysis 1B (τ2=0.01, Q= 
5.26, df=4, p=0.26), analysis 2A (τ2=0.01, Q= 4.97, df=4, p=0.29) and analysis 2B 
(τ2=0.01, Q= 6.17, df=4, p=0.19). The forest plots are displayed in Figure 4.5-
Figure4.8. 
 
Figure 4.5: Drug abuse problem severity. 12 months post-intake 1A 
 
  
Figure 4.6: Drug abuse problem severity. 12 months post-intake 1B 
 
 
 
Figure 4.7: Drug abuse problem severity. 12 months post-intake 2A 
 
Figure 4.8: Drug abuse problem severity. 12 months post-intake 2B 
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Drug abuse frequency 6 months post-intake 
Four studies reported data on the drug abuse frequency reduction. Three studies 
found a statistically significant effect that favoured MDFT (Liddle 2009, Rigter 2011 
and Liddle 2008). In Dennis 2004, MDFT was not significantly different from the 
MET/CBT5 treatment or from ACRA treatment. Pooled results showed a statistically 
significant effect of MDFT for drug abuse frequency reduction. The random effects 
weighted standardised mean difference (SMD) for analysis A was -0.24 (95% CI -
0.43 to -0.06, p=0.01), and for analysis B SMD=-0.25 (95% CI -0.40 to -0.11, 
p=0.0007). Heterogeneity of effects among studies was not statistically significant in 
analysis A (τ2=0.01, Q= 4.63, df=3, p=0.2) and analysis B (τ2=0.00, Q= 3.11, df=3, 
p=0.37). The forest plots are displayed in Figure 4.9 and Figure 4.10. 
 
 
Figure 4.9: Drug abuse frequency. 6 months post-intake A 
 
 
 
Figure 4.10: Drug abuse frequency. 6 months post-intake B 
 
 
Drug abuse frequency 12 months post-intake 
Two studies (Rigter 2011 and Liddle 2009) found a statistically significant effect that 
favoured MDFT, whereas the differences between treatments in Liddle 2008 and in 
Dennis 2004 were not statistically significant. Pooled results showed no statistically 
significant effect of MDFT for drug abuse frequency reduction. The random effects 
weighted standardised mean difference (SMD) for analysis A was -0.28 (95% CI -
0.63 to 0.07, p=0.11), and for analysis B SMD=-0.28 (95% CI -0.63 to 0.07, p=0.11). 
There was a statistically significant heterogeneity of effects among studies in 
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analysis A (τ2=0.10, Q= 15.43, df=3, p=0.001) and analysis B (τ2=0.10, Q= 15.45, 
df=3, p=0.001). The forest plots are displayed in Figure 4.11 and Figure 4.12. 
 
Figure 4.11: Drug abuse frequency. 12 months post-intake A 
 
 
 
Figure 4.12: Drug abuse frequency. 12 months post-intake B 
 
 
 
4.4.2 Secondary outcome results 
Family functioning 
It was not possible to perform a meta-analysis on family functioning. One study, 
Liddle 2001, used a rating scale that assessed the degree of family functioning from 1 
(optimal functioning) to 10 (severely dysfunctional). Family functioning was 
measured as a decrease; hence a negative effect size favours MDFT. Results showed 
no significant differences between MDFT and the MEI treatment either at 6 months 
post-intake, SMD =0.25 (95% CI -0.23, 0.73), or at 12 months post-intake, SMD =-
0.34 (95% CI -0.82, 0.15). Results showed no significant differences between MDFT 
and the AGT treatment at 6 months post-intake but a significant difference which 
favored MDFT at 12 months post-intake; SMD =-0.30 (95% CI -0.80, 0.21) at 6 
months post-intake and SMD =-1.26 (95% CI -1.81, -0.70) at 12 months post-intake, 
respectively.  
 
Liddle 2009 measured family functioning in terms of family interactions, measuring 
them separately as positive and as negative family interactions respectively. Results 
showed no significant differences between MDFT and the peer group comparison; 
SMD =-0.09 (95% CI -0.52, 0.34) at 6 months post-intake, SMD =0.13 (95% CI -
0.30, 0.56) at 12 months post-intake for positive family interactions, and SMD =-
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0.26 (95% CI -0.69, 0.17) at 6 months post-intake, and SMD =-0.25 (95% CI -0.69, 
0.18) at 12 months post-intake for negative family interactions.   
 
Rigter (2011) reported on family functioning measured in terms of conflict and 
cohesion11. Results showed no significant differences between MDFT and the TAU 
comparison; SMD =0.14 (95% CI -0.07, 0.35) at 6 months post-intake, SMD =0.19 
(95% CI -0.01, 0.41) at 12 months post-intake for family conflict, SMD =-0.15 (95% 
CI -0.36, 0.06) at 6 months post-intake, and SMD =-0.16 (95% CI -0.36, 0.05) at 12 
months post-intake for family cohesion.   
 
 
Figure 4.13: Family functioning.   
 
Figure 4.14: Positive family interaction.  
  
 
Figure 4.15: Negative family interaction.   
 
 
 
 
 
 
                                                        
11 Reported in Schaub et al., 2014. 
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Figure 4.16: Family conflict. 
 
 
 
Figure 4.17: Family cohesion. 
 
 
 
Education or vocational involvement 
Two studies (Liddle 2001, and Liddle 2009) provided data that enabled the 
calculation of an effect size for the education outcome as measured by grade point 
average. 
 
Grade point average 6 months post-intake 
Grade point is measured as a decrease; hence a negative effect size favours MDFT.  
One study (Liddle 2009) found statistically significant differences that favored 
MDFT, whereas the differences in Liddle 2001 study were not statistically 
significant. Pooled results did not show a statistically significant effect of MDFT for 
school grade improvement when using the AGT comparison in the Liddle 2001 and 
a marginal statistically significant effect when using the MEI comparison in Liddle 
2001. The pooled estimate were SMD =0.38 (95% CI -0.25, 1.01) and SMD =0.47 
(95% CI 0.01, 0.92). There was no statistically significant heterogeneity between 
studies in any of the analyses (τ2=0.15, Q= 3.54, df=1, p=0.06 and τ2=0.05, Q= 1.96, 
df=1, p=0.05). However, effect sizes differ markedly and with only two studies the 
power to detect heterogeneity is very low. 
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Figure 4.18: Grade point average. 6 months post-intake 1 
 
 
 
 
Figure 4.19: Grade point average. 6 months post-intake 2 
 
 
Grade point average 12 months post-intake 
No data were provided. 
 
Retention 
We used the information reported in all five studies that came closest to the 
proportion of cases with full completed treatment. Results were measured as odds 
ratio (OR) non-event, implying that an OR of less than one favours MDFT. 
 
Three studies (Liddle 2008, Liddle 2001 and Dennis 2004) found no difference 
between retention rates. In the remaining two studies, the difference between 
retention rates between treatments favored MDFT (Rigter 2011 and Liddle 2009) 
and was statistically significant. Note that the magnitudes of the effect sizes of these 
two studies and the width of the confidence intervals were quite distinct from the 
three other studies (Liddle 2001, Liddle 2008 and Dennis 2004). 
  
Pooled results showed a statistically significant effect of MDFT for retention when 
using the AGT comparison in Liddle 2001, but the effect was not statistically 
significant when using the MEI comparison in Liddle 2001. 
 
The random effects weighted odds ratio (OR) for analysis 1A was 0.44 (95% CI 0.21 
to 0.94, p=0.03), for analysis 1B OR=0.45 (95% CI 0.21 to 0.95, p=0.04), for 
analysis 2A OR=0.48 (95% CI 0.22 to 1.05, p=0.07) and for analysis 2B OR=0.49 
(95% CI 0.22 to 1.07, p=0.07). There was statistically significant heterogeneity of 
effects among studies in analysis 1A (τ2=0.54, Q= 21.92, df=4, p=0.0002), analysis 
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1B (τ2=0.55, Q= 22.15, df=4, p=0.0002), analysis 2A (τ2=0.60, Q= 23.80, df=4, 
p<0.0001) and analysis 2B (τ2=0.60, Q= 23.97, df=4, p<0.0001). The forest plots 
are displayed in Figure 4.18-Figure 4.21. 
 
Figure 4.20: Retention.1A 
 
 
Figure 4.21: Retention.1B 
 
 
Figure 4.22: Retention.2A 
 
 
Figure 4.23: Retention.2B 
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Risk behavior 
One study, Rigter 2011, provided data on externalizing disorders/symptoms (e.g. 
aggression and delinquency) measured by the Youth Self-report and the Child 
Behavior Checklist. Results showed no significant differences between MDFT and 
TAU on either of the scales; SMD =-0.02 (95% CI -0.23, 0.18) at 6 months post-
intake and, SMD =-0.02 (95% CI -0.22, 0.19) at 12 months post-intake for the YSR 
scale; SMD =-0.01 (95% CI -0.20, 0.22) at 6 months post-intake and SMD =-0.02 
(95% CI -0.23, 0.19) at 12 months post-intake for the CBCL scale.  
 
Figure 4.24: Externalizing symptoms.  
 
 
 
 
 
 
 
 
 
 
 
One other study, Liddle 2009, provided delinquency measures. No significant 
differences between MDFT and peer group were found at either at 6 months post-
intake, SMD =-0.28 (95% CI -0.71, 0.16), or at 12 months post-intake, SMD =-0.33 
(95% CI -0.76, 0.10). 
 
Figure 4.25: Delinquency 
  
 
Other adverse effects  
No other adverse effects (such as rates of hospitalization, suicide or over-doses) were 
provided in any of the five studies. 
4.4.3 Sensitivity analysis 
Sensitivity analyses were performed for the primary outcomes; drug abuse problem 
severity and drug abuse frequency. We examined the robustness of conclusions 
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when the studies scoring 4 on the incomplete outcome data item (Liddle 2001 and 
Liddle 2008) and the other bias item (Liddle 2008 and Rigter 2011) respectively 
were removed from the analyses. The results are displayed in table 4.4.1 and 4.4.2. 
 
Table 4.4.1  Sensitivity analyses, drug abuse problem severity. 
 
SMD [CI 95%]  Drug abuse problem 
severity, 6 months post-
intake 
Drug abuse problem 
severity, 12 months post-
intake 
All studies 1A -0.35 [-0.59, -0.11] -0.25 [-0.39, -0.10] 
1A Excluded: Incomplete data score 
4 
-0.25 [-0.52, 0.03] -0.29 [-0.50, -0.08] 
1A Excluded: Other bias score 4 -0.48 [-0.92, -0.04] -0.33 [-0.62, -0.05] 
All studies 1B -0.33 [-0.59, -0.08] -0.23 [-0.39, -0.06] 
1B Excluded: Incomplete data score 
4 
-0.22 [-0.52, 0.08] -0.27 [-0.52, -0.01] 
1B Excluded: Other bias score 4 -0.45 [-0.96, 0.05] -0.31 [-0.66, 0.04] 
All studies 2A -0.31 [-0.53, -0.10] -0.27 [-0.43, -0.11] 
2A Excluded: Incomplete data score 
4 
-0.25 [-0.52, 0.03] -0.29 [-0.50, -0.08] 
2A Excluded: Other bias score 4 -0.42 [-0.79, -0.04] -0.38 [-0.68, -0.08] 
All studies 2B -0.30 [-0.53, -0.07] -0.25 [-0.43, -0.07] 
2B Excluded: Incomplete data score 
4 
-0.22 [-0.52, 0.08] -0.27 [-0.52, -0.01] 
2B Excluded: Other bias score 4 -0.39 [-0.84, 0.05] -0.36 [-0.73, 0.01] 
 
For drug abuse problem severity, the SMD remains statistically significant and still 
favours MDFT for most of the comparisons at the 12 post-intake when the studies 
scoring 4 are removed.  However, the effect becomes no longer significant at 6 
months post-intake when studies scoring 4 on the incomplete outcome data item are 
removed. The relative reduction remains significant and becomes larger for two of 
the contrasts (1A & 2A) at 6 months post-intake when studies scoring 4 on the other 
bias item are removed.  
 
In both cases the relative reduction becomes marginally smaller at 12 months post-
intake. As expected, when studies are removed from the analysis the confidence 
intervals become wider; there is however considerably overlap between confidence 
intervals (a graphical display is given in section 11).  At 6 months post-intake, the 
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results (with one exception12) are no longer statistically significant whereas they are 
still statistically significant at the 12 post-intake (with two exceptions13). 
 
Table 4.4.2  Sensitivity analyses, drug use frequency. 
SMD [CI 95%]  Drug use frequency, 6 
months post-intake 
Drug use frequency, 12 
months post-intake 
All studies A -0.24 [-0.43, -0.06] -0.28 [-0.63, 0.07] 
Excluded A: Incomplete data score 
4 
-0.21 [-0.44, 0.02] -0.35 [-0.82, 0.12] 
A Excluded: Other bias score 4 -0.21 [-0.68, 0.26] -0.43 [-1.45, 0.59] 
All studies B -0.25 [-0.40, -0.11] -0.28 [-0.63, 0.07] 
Excluded B: Incomplete data score 
4 
-0.23 [-0.41, -0.05] -0.35 [-0.82, 0.12] 
B Excluded: Other bias score 4 -0.24 [-0.63, 0.15] -0.43 [-1.45, 0.59] 
 
For drug use frequency, the SMD ceases to be statistically significant for most of the 
comparisons when studies scoring 4 are removed.  
 
At 6 months post-intake, the results are no longer statistically significant when the 
comparison used in Dennis 2004 is MET/CBT5 whereas they are still statistically 
significant when the comparison used in Dennis 2004 is ACRA.  
 
                                                        
12 Analysis 1A when removing studies scoring 4 on the other bias item. 
13 Analysis 1B and 2B when removing studies scoring 4 on the other bias item. 
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5 Discussion  
5.1  SUMMARY OF THE MAIN RESULTS 
Our main objective was to evaluate the current evidence on the effect of MDFT on 
drug abuse reduction for young people in treatment for non-opioid drug abuse. 
Further objectives of this review were to examine the moderators of drug abuse 
reduction effects and to examine whether MDFT works better for particular groups. 
Unfortunately it was not possible to assess this second review objective because of 
the limited number of studies. 
 
Five randomized controlled trials of MDFT met the inclusion criteria for this review. 
All five studies compared MDFT to other treatments, mainly CBT or ‘CBT-informed’ 
interventions, thus it was not possible to analyze the absolute effect of MDFT.  Two 
studies, Liddle 2001, and Dennis 2004, had two comparison groups with different 
individuals, and the Rigter 2011 study was carried out in five different countries with 
treatment as usual as the comparison condition, which varied across countries. The 
comparison treatments in the five studies were: Cognitive Behavioral Therapy 
(CBT), peer group, treatment as usual (TAU), adolescent group therapy 
(AGT)/multifamily educational therapy (MEI) and Motivational Enhancement 
Therapy/Cognitive Behavioral Therapy (MET/CBT5)/Adolescent Community 
reinforcement approach (ACRA). 
 
The outcomes were reported at varying time points. We grouped the outcomes at 6 
and 12 months post-intake. As duration of treatment in two studies was 3-4 months 
and in three studies was 4-6 months, these time points were approximately 
equivalent to termination and 6 month follow-up respectively. 
 
In summarising these results, we have chosen to interpret a value of the standardised 
mean difference, SMD=0.20 as a small effect size, as is the general practice (Cohen, 
1988). 
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Abstinence or reduction of drug abuse 
Meta-analysis of the five included studies show a small but statistically significant 
effect of MDFT for youth drug abuse problem severity reduction at 6 months post-
intake and 12 months post-intake compared to CBT, TAU, MET/CBT5 and ACRA. 
The pooled effect sizes are however small and confidence intervals are often close to 
zero. The statistically significance of the pooled results are sensitive to the removal 
of studies with methodological weaknesses at 6 months post-intake but not at 12 
months post-intake.  The available data thus supports the hypothesis that there is an 
effect on drug abuse problem severity reduction of giving MDFT to young drug 
abusers compared to other treatments.  
 
Pooled results of the four studies providing data on drug abuse frequency reduction 
favours MDFT compared to CBT, TAU, MET/CBT5 and ACRA. The effect of MDFT 
for youth drug abuse frequency reduction is small and statistically significant at 6 
months post-intake but there is no statistically significant effect at 12 months post-
intake. The statistically significance of the pooled results are sensitive to removal of 
studies with methodological weaknesses at 6 months post-intake in one of two 
analyses (when the comparison used in Dennis 2004 is MET/CBT5).   
 
The available data supports the hypothesis that there is a small drug abuse 
frequency reduction effect of giving MDFT to young drug abusers compared to other 
treatments at 6 months post-intake, but the effect appears to vanish 12 months after 
intake. 
 
When interpreting these results, however, consideration should be given to the 
limited number of studies providing data that enables a calculation of an effect size 
regarding drug abuse reduction. The conclusions that can be drawn from giving 
MDFT to young drug abusers compared to other treatments14 would be more 
convincing if more studies were available. The pooled effect sizes are small and 
confidence intervals are often close to zero.   
 
Family functioning 
It was not possible to perform a meta-analysis on family functioning as only three 
studies provided data and the measures used were not comparable. 
 
                                                        
14 The comparison treatments were: Cognitive Behavioral Therapy (CBT), peer group, treatment as 
usual (TAU), adolescent group therapy (AGT)/multifamily educational therapy (MEI) and Motivational 
Enhancement Therapy/Cognitive Behavioral Therapy (MET/CBT5)/Adolescent Community 
reinforcement approach (ACRA). 
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School grades 
Two studies reported school grades; however, only data at 6 months post-intake 
were provided. Meta-analysis favors MDFT compared to peer group and AGT/MEI; 
however confidence intervals are wide. The effect of MDFT for improving school 
grades is not statistically significant when using the AGT comparison in Liddle 2001 
but is statistically significant when using the MEI comparison in Liddle 2001. 
 
Retention 
We extracted data on retention from all five included studies; meta-analysis 
favoured MDFT. Overall the results indicate that retention may be positively 
affected by structured MDFT treatment compared to the less structured control 
conditions of CBT, TAU, MET/CBT5 and ACRA.  
However the pooled results must be interpreted with caution as two studies stand 
out from the others with large effect sizes and very wide confidence intervals (Liddle 
2009 comparing MDFT to peer group, and Rigter 2011 comparing MDFT to TAU), 
and the estimated between study variation is quite large.  
 
Risk behavior and other adverse effects  
Opportunities for meta-analysis were limited for risk behavior as only one study 
(Rigter 2011) reported relevant data. No other adverse effects such as rates of 
hospitalization, suicide and over-doses were provided in any of the five studies. 
 
5.2  OVERALL COMPLETENESS AND APPLICABILITY OF 
EVIDENCE 
The number of included studies in this systematic review is small; only five trials 
met the inclusion criteria and examined whether MDFT reduced youth drug use. 
Three of these were conducted by MDFT program developers, one was conducted by 
an independent investigator with a program developer as a co-author and one study 
was conducted by independent investigators. 
 
It was not possible to analyze the absolute effect of MDFT. All five studies compared 
MDFT to other interventions, mainly CBT or ‘CBT-informed’ treatments. Two 
studies had two comparison groups with different individuals and different 
treatments, while the study which was carried out in five different European 
countries had variations in comparison treatments across countries.  
 
The five trials were reported in 16 papers, and we looked for and extracted relevant 
outcome data in all 16 papers. Studies of secondary analyses of the included trials 
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(Hogue, Dauber, Samuolis, & Liddle, 2006; Hogue et al. 1998; Henderson, Dakof, 
Greenbaum, & Liddle, 2010; Henderson, Rowe, Dakof, Hawes, & Liddle, 2009; 
Shelef, Diamond, Diamond, & Liddle, 2005) did not provide any additional data for 
this review because they analysed subgroups of participants and/or explored for 
factors which moderate treatment effects. 
 
It was possible to analyse outcomes at 6 and 12 month post-randomization 
(approximately equivalent to 6 and 12 months post-intake), although not all studies 
provided data at the longer follow up which would have allowed for documentation 
of accumulated or longer-term effects.  
 
Whilst it was possible to include all studies in the analysis of the primary outcome 
reduction of substance abuse, reporting of secondary outcome data was very limited. 
 
Four of the five studies originated from North America. This may limit the 
applicability of the evidence to a specific social and cultural setting, which in turn 
may be difficult to translate to other settings. This indicates a need for more well-
conducted studies of CBT interventions in countries other than the USA. 
 
5.3  QUALITY OF THE EVIDENCE 
All five included studies were randomized controlled trials but none can be 
characterised as a robust RCT with low risk of bias on all assessed risk of bias items.  
One of the five included studies provided insufficient information on core issues to 
allow us to assess the risk of bias and had a significant level of missing data, making 
us question its validity.  
 
Where effects were statistically significant, there was overall consistency in the 
direction of treatment effects regarding primary outcome (drug problem severity 
and drug abuse frequency) with all treatment effects favouring MDFT. Similarly, 
where effects on retention were statistically significant, MDFT was the favoured 
treatment. However the overall result must be interpreted with caution as two 
studies stand out from the others, with large effect sizes and very wide confidence 
intervals, and the estimated between study variation is quite large. 
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5.4  POTENTIAL BIASES IN THE REVIEW PROCESS 
The narrow search strategy performed in this review may limit the likelihood of 
finding all relevant studies. However, we attempted to minimize the risk of missing 
relevant studies by conducting an extensive search for grey literature, an extensive 
hand searching and by contacting international experts within the field of MDFT; 
indeed, the large number of grey literature and hand searched literature that has 
been assessed for relevance attests to this effort.   
 
5.5  AGREEMENTS AND DISAGREEMENTS WITH OTHER 
STUDIES OR REVIEWS 
We identified five narrative reviews and three quantitative reviews on MDFT 
treatment for drug-using youth. 
 
The identified narrative reviews (Thompson, Pomeroy, & Gober, 2005; Austin, 
Macgowan, & Wagner, 2005; Szapocznik, Lopez, Prado, Schwartz, & Pantin, 2006; 
Liddle, 2010; and Rowe, 2010) report a general pattern of a positive effect for MDFT 
treatment for drug-using youth. Thompson et al., 2005; Austin et al., 2005, and 
Szapocznik et al., 2006 review several interventions for drug-using youth, and with 
the exception of Thompson et al., 2005, their conclusions concerning MDFT are 
based on one study (Liddle 2001). In contrast, Liddle, 2010 and Rowe, 2010, focus 
on MDFT and base their conclusions on a greater number of studies. 
 
We identified three quantitative reviews (Bender, Tripodi, Sarteschi, & Vaughn, 
2011; Waldron & Turner, 2008; Vaughn et al., 2004). Vaughn et al., 2004, examined 
several interventions for drug-using youth and the conclusions concerning MDFT 
were based solely on Liddle 2001 with the authors reporting “evidence of clinically 
meaningful effect (Evidence Summary [ES] > .20) with at least 1 year follow-up or 
replication and using relatively strong designs”. 
 
Waldron & Turner, 2008, used meta-analysis to evaluate family therapy, CBT 
(individual and group), and ‘minimal treatment control conditions’ for drug-using 
youth. They concluded that “MDFT, FFT and group CBT emerged as well-
established models for substance abuse treatment.” based on the studies by Liddle 
2001, Liddle 2008, Liddle 2009 and Dennis 2004. 
 
Bender et al., 2011 used meta-analysis to evaluate family therapy and individual 
therapy for drug-using youth. The authors reported that “Interventions with large 
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effect sizes (>.80) included several family-based or multisystem approaches 
(Integrated Family, CBT, MDFT, Teaching family).” based on the studies by Liddle 
2001, Liddle 2008 and Liddle 2009. 
 
Consistent with our expectations, the apparent feedback from the three reviews is 
that more research is needed, not least with regard to moderators and identification 
of which particular subgroups of youth may be more likely to respond to specific 
interventions, as well as how treatments can be adapted or tailored to the individual 
needs of a young person to improve drug abuse outcomes. These are similar issues 
to those we planned to assess in our review. However, the lack of empirical evidence 
obscured the possibility of assessing moderators of effect and effects on subgroups. 
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6 Authors’ Conclusion 
6.1  IMPLICATIONS FOR PRACTICE 
Although most of the few available studies on effectiveness are characterized by 
methodological problems, the results of this review suggest that MDFT seems to 
‘work’ in the sense that the intervention results in a slightly higher reduction of drug 
abuse for the average individual compared to the average individual receiving other 
active treatments. Besides knowledge of whether a certain intervention ‘works’,  in 
the sense that it is effective for the average individual, practitioners need knowledge 
about potential differential effects on treatment of highly relevant participant 
characteristics such as age, gender, minority background, family composition (e.g., 
single parents), and co-occurring conditions.   
 
However, the participant characteristics listed above are potential predictors of 
treatment outcome, and practitioners need to be able to tailor the program to 
particular types of young drug abusers. It is not possible to identify which particular 
subgroups of youth may be more likely to respond to specific interventions, and 
subsequently how treatments could be adapted or tailored to the individual needs of 
a young person until results of additional MDFT outcome studies are available. 
 
Programmes for drug using youth are costly, and it is also possible that such 
initiatives have potential cause damage to some individuals. The available evidence 
points to small effect sizes of MDFT in comparison to other treatments. Taking the 
individual variation in treatment effects into consideration, we cannot rule out the 
possibility that MDFT may be counterproductive for some individuals. It is therefore 
crucial to know more about its effectiveness in order to determine where money is 
best allocated as well as to understand which form of support would benefit young 
drug abusers most. 
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6.2  IMPLICATIONS FOR RESEARCH 
It is important to address the need for more research in the field. A small body of 
evidence exists in relation to the treatment of young drug abusers, with only a very 
modest number of controlled evaluations of treatments for this group. Most of the 
few available studies of effectiveness have methodological problems, such as small 
sample size and varied methods of assessing drug abuse; such problems make 
definitive conclusions difficult, if not impossible. Well-designed, randomized 
controlled trials within this population are needed and should be reported clearly in 
accordance with the principles of the CONSORT 2010 statement. In addition, longer 
follow up data should be available in future studies. 
 
It is also important to consider the possibility of any adverse effects these 
interventions might have. The popular belief is that MDFT, as well as other family 
therapy approaches, is harmless, but very little research has been conducted that 
focuses on the potential harm of such family therapy approaches. 
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9 Characteristics of studies 
9.1  CHARACTERISTICS OF INCLUDED STUDIES 
Dennis  2004  
Methods Design: RCT (2 trials, 3 intervention arms in each –total in both sites n=600 randomly 
assigned. Only relevant trial reported here) total n= 300  
 
Country/city/area: four treatment sites: University of Connecticut Health Center 
(UCHC), Operation PAR, Chestnut Health Systems (CHS), and Childrens Hospital of 
Philadelphia (CHOP). It was not logistically feasible to implement all five conditions in 
any one site because of the limits of case flow and resources. (The UCHC site, 
located in Farmington, CT, is a major academic medical center that has been 
involved in multiple substance abuse treatment trials. The Operation PAR site, 
located in St. Petersburg, is Florida’s most comprehensive adolescent treatment 
provider and also offers behavioral healthcare services in three additional Florida 
counties. The CHS site in Madison County is Illinois largest community based 
adolescent treatment provider and also operates other programs in the state. CHOP, 
located in Philadelphia, PA, is a leading pediatric research center and has been 
involved in numerous substance abuse treatment and family therapy trials. The sites 
differed in their catchment areas, with CHS serving a rural and small urban population 
at three facilities located 30 miles apart, CHOP primarily targeting the inner city of 
Philadelphia, and UCHC and PAR serving suburban areas.) 
 
Number of sites: 4 sites  
Participants  Age: 12 to 18 years (13% aged 13-14, 53% aged 15-16, 34% aged 17-18). 
 
Gender: 81% male.  
 
Ethnicity: 49% White/ Caucasian, 2% Hispanic/Latino,   47% African American /Black 
and 2 % Other. 
 
Family status: 55% from single parent families. 
 
Main drug of use: Cannabis.  
 
Severity: 100% met criteria for a cannabis related disorder, 41% alcohol disorder, 
12% other sub use disorder.  
 
Comorbidity:  35%  internal disorder, 63% external disorder, 63% physicial, sexual or 
emotional victimization, 67% violence & illegal activity (excluding possession/use of 
drugs), 84% 3-12 in number of substance psychological or legal problems. 
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Inclusion criteria:  One or > DSM-IV criteria for cannabis abuse or dependence, used 
cannabis in the past 90 days or 90 days prior to being sent to a controlled 
environment, and were appropriate for outpatient or intensive outpatient treatment. 
 
Exclusion criteria:   (a) reported use of alcohol 45 or > of the 90 days prior to intake; 
(b) reported use of other drugs 13 or > of the 90 days prior to intake; (c) reported 
acute medical or psychological problem likely to prohibit full participation in tx. (d) 
insufficient mental capacity to understand and provide informed consent or participate 
(e) lived outside of the program's catchment area; (f) history of repeated, violent 
behavior or severe conduct disorder that might put other participants at risk; or (g) 
lacked sufficient ability to use English to participate in the consent process, treatment, 
or research interviews. 
Interventions Intervention: Multidimensional Family Therapy MDFT (n= 100) 
 
Duration: 12 to 15 sessions over a period of 12 to 15 weeks. 6 session with the youth, 
3 with parents, & 6 with whole family 
 
Comparison(s): Alternative intervention(s ) 
1. Adolescent Community reinforcement approach (ACRA) (n=100) 
ACRA incorporates elements of operant conditioning, skills training, and a social 
systems approach.12 – 14 sessions over 12 to 14 weeks.  4 of the session include 
parents. 
 
2. Motivational Enhancement Therapy (MET) / Cognitive Behavioral Therapy 
(MET/CBT 5).  n=100  
MET designed to help adolescents see the relationship between cannabis use and its 
consequences so they will conclude that the costs of cannabis use outweigh its 
benefits.  
CBT intervention teaches basic skills for (a) refusing offers of cannabis, (b) 
establishing a social network supportive of recovery, (c) developing a plan for 
pleasant activities to replace cannabis-related activities, and (d) coping with 
unanticipated high-risk situations, problem solving, and recovering from relapse, 
should one occur. 
 
Duration: Brief intervention 
5 sessions in total. 2 individual MET sessions and three group CBT sessions over 6 
to seven weeks. (no family counseling)   
 
Relevant 
Outcomes 
 
Baseline 
3mth from 
BL (end Tx) 
6mth from 
BL (3m 
endtx 
9mth from 
BL (6 end tx)  
12mth from 
BL (9m – tx) 
Primary outcomes: 
(a) Drug use frequency measured by GAIN’s Substance Frequency Scale 
(b) Drug use problem severity, measured by GAIN’s Substance Problem Scale 
(c) days of abstinence between the randomization date and the 12-month follow 
up interview     
(d) whether the adolescent was in recovery at the end of the study 
Measures: Global Appraisal of Individual needs (Dennis et al. 1998), the drug use 
frequency was measured using objective (urine samples) and collateral verification at 
baseline, 3 and 6 months 
 
Secondary outcomes: None reported, except retention (having completed 75% of the 
planned dosage) 
 
 
Liddle  2008 
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Methods Design: RCT, n=224 randomly assigned (2 intervention arms, CBT=112, MDFT=112) 
 
Country/city/area : Community-based drug abuse clinic in the Northeastern United 
States 
 
Number of sites: 1 
Participants  Age: 12 to 17.5 years old – mean:15.4 (1.23) 
 
Gender:  81% male 
Ethnicity: 72% African American, 18% White Non-Hispanic, & 10% Hispanic 
 
Family status:  n (%) Single parent:  MDFT 67 (60%) CBT 62 (55%) ALL 129 (58%). 
Two parents: MDFT 22 (20%) CBT 16 (14%) ALL 38 (17%). Blended:  
MDFT 14 (13%) CBT 20 (18%) ALL 34 (15%). Other: MDFT 9 (8%) CBT 14 (13%) 
ALL 23 (10%) 
 
Main drug of use:  Cannabis  
 
Severity:  at baseline,  all youth were drug users with 75% meeting DSM-IV criteria for 
cannabis dependence 
 
Comorbidity:   Numbers reported but not type of comorbid condition. Number of 
comorbid [M (SD)] MDFT 2.63 (2.1) , CBT 2.47 (2.0),  ALL 2.55 (2.1) 
 
Inclusion criteria:   
Between the ages of 12 and 17.5 years;  living with at least one parent or parent-
figure who could participate in the family therapy if assigned to that condition;   
 
Exclusion criteria: 
Participants must have no history of organic dysfunction; not currently be in need in-
patient detoxification; and not be actively suicidal.  
  
Interventions Intervention:  MDFT (manual: focus on 4 independent according to the particular risk 
and protection profile of the youth and family. The 4 domains are: Adolescent, Parent, 
Interaction and Extra familial) 
 
Mode: Combination. Each weekly session typically included a family session, and a 
session with the parent alone and/or the adolescent alone. 
Duration: weekly sessions (60-90 min), over 4 to 6 months. 
 
 
Comparisons: Alternative interventions  
CBT manual based 
The adolescent-focused CBT used in this study was also influenced by dialectal 
behavior therapy. 
 
Mode: Individual  
Duration:  weekly sessions (60-90 min), over 4 to 6 months. 
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Relevant 
Outcomes 
 
Baseline 
Termination 
1st FU 6mths 
post tx 
2nd FU 12 
months post 
tx  
Primary outcomes: 
 
Drug problem severity, cannabis use, other drug use  & abstinence  (30 –day minimal 
use) 
 
Measured by TLFB , Personal experience inventory (PEI) for drug problem severity 
 
Secondary outcomes: 
 
Not reported as an outcome:  Authors report "no differences between groups on 
treatment retention” and median number of sessions was eight. 
 
 
 Liddle  2001 
Methods Design: RCT  (three treatment groups, total n=182 randomly assigned ) 
 
Country/city/area: US 
 
Sites: Not reported 
Participants  Age: Between 13 and 18 years mean:15.9 (1.4) 
Gender: 80% males 
Ethnicity: 51% white, non-Hispanic; 18% African-American; 15% Hispanic; 6% Asian; 
and 10% other. 
Family status: 31% came from two-parent households, 48% from single parent 
households, and 21% from stepfamilies. 
Main drug of use: 51% were polydrug users, while 49% were strictly marijuana and 
alcohol users. 
Severity: Adolescents had been using drugs for an average of 2.5 years Pg 658).were 
using any illegal substance other than alcohol at least three times per week. Alcohol 
use could be greater or less than three times per week (pg. 657). 
Comorbidity:  NR 
 
Inclusion criteria:  Between 13 and 18 years old, using any illegal substance other 
than alcohol at least three times per week. 
Exclusion criteria: 1)No history of mental retardation or organic dysfunction,2) did not 
require inpatient detoxification, 3)not be involved in any other form of psychotherapy-
oriented drug treatment or any Alcoholics Anonymous (AA) or Narcotics Anonymous 
(NA) treatment at the time of referral 
Interventions Intervention: MDFT (n= 47) (70 % completers, n=33) 
There were 182 cases assigned to treatment, with 30 (16%) classified as refusing 
treatment since they failed to attend even one therapy session. Of the remaining 152 
cases, 47 were assigned to MDFT 
 
Duration: 16 sessions, app. once a week (5 months) 
 
Comparison(s):  
1) MEI (n=52) (65 % completers, n=34). The MEI treatment blended features of 
psychoeducational and multifamily interventions. Multifamily groups have a 
strong history in family therapy. This treatment was guided by theoretical 
principles from family systems and social support theory generally and from 
psychoeducational approaches to family intervention in particular. The 
intervention format consisted of focused and structured, content-specific 
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group discussions, didactic presentations that included handouts, skill-
building exercises, individual family problem solving within a group meeting 
of several families, and homework assignments. Intervention content 
consisted of learning alternative forms of stress reduction, family and 
individual risk and protective factors, improving family organization rules and 
limit setting, and improving family communication and problem-solving 
abilities...(..)..structured in three parts: (a) didactic presentation (informal and 
conversational vs. formal lecture) by the leader, (b) topic focused intrafamily 
and/or interfamily group discussion, and (c) skill-building exercises. Families 
received workbooks with content summaries of the session foci and activities 
2) Adolescent Group Therapy, AGT, (n=53) (53 % completers, n=28). In this 
study, the group therapy approach was an adaptation of Beck’s (88, 89) 
group therapy model. This intervention is based on phases of group 
development, with different therapeutic tasks and goals assigned to each 
phase. The emphasis was on developing individual social skills such as 
communication, self-control, self-acceptance, and problem solving, as well 
as building social support among group members. Didactic presentations, 
group discussions, and group skill-building exercises were initiated in a 
decidedly noncoercive manner to establish participation and trust. Treatment 
began with two individual family sessions to enlist cooperation, outline the 
goals and format of the treatment, and discuss group rules and procedures. 
In these family sessions, the therapist tried to enlist and facilitate parental 
support of and cooperation in the treatment........Phase 2 of the AGT model 
had four structured adolescent group therapy sessions that began with 
member introductions and discussions of confidentiality and limit 
setting.......Phase 3 was the skill-building phase.... 
 
Duration:  
1) MEI: 14-16 weeks, 90 min. each (Treatment dosage and duration were 
equalized across the three intervention groups. Each of the three treatments 
consisted of a minimum of 14 and a maximum of 16 weekly sessions, which 
occurred over a period of 5 to 6 months) 
2) AGT: Same as above.. 
 
 
Relevant 
Outcomes 
 
Intake 
Termination 
6 months 
follow-up 
12 months 
follow-up 
 
Primary outcomes: 
- Drug use - adolescent self-report, collateral report (parent report), and 
urinalysis data were gathered for each adolescent. Information from these 
three data sources were assessed by three experienced clinician-raters and 
used to classify drug use consumption on a 15-point scale by the clinician-
raters. 
 
Secondary outcomes: 
- Problem Behaviors, measured by the Acting Out Behaviors Scale (parent 
report) 
- School Performance measured by average grades 
- Family Functioning, measured by a rating scale (Global Health Pathology Scale 
of the Beavers Interactional Competence Scales) that assesses the degree 
of family functioning rated from 1 (optimal functioning) to 10 (severely 
dysfunctional). 
- Retention/Attrition measured as client-initiated termination after the first session 
and before session 14 or refusing to return for the post treatment 
assessment battery 
 
Liddle  2009 
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Methods Design: RCT   (MDFT vs. Peer Group Therapy ) N=83 randomly assigned 
 
Country/city/area: Miami, village inc., a non-profit community drug abuse treatment 
clinic 
 
Sites: 1 
Participants  Age: 11-15 years (average 14 years, M=13.73, SD 1.1) 
Gender: 58 males, 22 females 
Ethnicity: 42 % Hispanic, 38 % African American, 11 % Haitian/ Jamaican, 3 % non-
Hispanic White and 4 % other 
Family status: 53% living with single parent 
Main drug of use: NR 
Severity: At intake, 47% met ASAM criteria for substance abuse, and 16% met criteria 
for substance dependence 
Comorbidity:  Many of the youths met criteria for comorbid psychiatric disorder;.39% 
conduct disorder, 29% ADHD, and 9% depressive disorder 
 
Inclusion criteria:  a) 11-15ys, b) referred for outpatient treatment for a substance 
abuse problem (ASAM criteria), c) living with at least one parent or parent-figure who 
could participate in the assessments and therapy 
Exclusion criteria: d) not in need of inpatient detoxification, e) not have had more than 
three previous arrests, f) not report using any substance more than three times per 
week, g) not suicidal, psychopathic or mentally retarded 
Interventions Intervention: MDFT (n=40  randomly assigned, 97% completed) 
 
Duration: twice per week, 90 min per time, 12 to 16 weeks 
 
Comparison(s): Peer group therapy (n= 43 randomly assigned, 72% completed) 
Manual-guided intervention based on social learning therapy and cognitive behavioral 
therapy - drew from guidelines and manual for conducting group CBT…. The 
treatment used a risk and protective factor framework, seeking to reduce substance 
use both by targeting directly and by focusing on risk factors such as low self-esteem, 
school failure and poor social functioning. Themes of self management, self efficacy, 
and coping with difficult stressful everyday life events were addressed. in all six 
content modules: drug education, self esteem, values and identity, decision making, 
personal control and interpersonal communication 
 
Duration: twice per week, 90 min per time, 12 to 16 weeks 
 
 
Relevant 
Outcomes 
 
Baseline 
6 weeks 
follow up 
Termination  
6 month 
follow-up 
12 month 
follow-up 
 
Primary outcomes: 
- Drug use frequency and problem severity (log transformed reported but non 
transformed kindly provided by Prof. Liddle on request) 
Measured by TLFB  and Problem Oriented Screening Instrument for Teenagers 
(POSIT) for drug problem severity 
 
 
Secondary outcomes: 
- Delinquency measured by juvenile justice records and the National Youth 
Survey Self-report Delinquency Scale (SRD) (log transformed) 
- Internalizing symptoms measured by the Global Appraisal of Individual needs 
(GAIN) General Mental Distress Index 
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 - Family functioning (separately as positive family interactions and negative 
family interactions respectively) measured by the Adolescent Daily Interview 
self-report checklist of family interactions. 
- Peer risk factors measured by the National Youth Survey Peer Delinquency 
Scale  
- School risk factors measured by academic grades, conduct grades and 
absences 
- Retention (did not discontinue treatment) 
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Rigter  2011 
Methods Design: RCT   (TAU and MDFT ) N=450 cases (450 randomized across four 
countries, 13 extra in TAU in France (not included in the report)) 
 
Country/city/area /Sites: Compares MDFT with treatment as usual (TAU) at and 
across sites in Brussels, Berlin, Paris, The Hague and Geneva. 
Participants  Age: 13-18 years (Average 16 years (M=16.3, SD 1.2) no significant differences 
between sites) 
Gender:  Average 86 % males. 80-96% male across sites (differs significantly) 
Ethnicity: 'Foreign descent' 25-73% (differs significantly across sites) 
Family status: The vast majority of adolescents were still living with family, i.e., their 
parents or other relatives. Otherwise not reported. 
Main drug of use: Cannabis 
Severity: Mean number of days of cannabis use 47-68. Most youth qualified for the 
diagnosis ‘cannabis dependence’ (84% across sites). 
Comorbidity: NR   
 
Inclusion criteria:  Eligible for INCANT are adolescents from 13 through 18 years of 
age with a cannabis use disorder (dependence or abuse), with at least one parent 
willing to take part in the treatment. 
 
Exclusion criteria: NR 
Interventions 
Intervention: MDFT (n=212). MDFT was delivered by individual therapists who were 
part of teams of 3 ‐ 5 therapists trained and certified by Miami, with one of the team 
members additionally serving as team supervisor. MDFT had to be carried out 
according to the MDFT treatment manual 
 
Duration: MDFT was to last about 6 months 
 
Comparison(s): TAU (n=238). TAU varied between the participating countries, but 
had elements in common: Belgium and the Netherlands was predominantly CBT, 
France and Switzerland had psychodynamic approaches included and Germany 
was in between the two pairs of other countries. TAU sessions were individual. 
 
Duration: The duration of TAU was similar to MDFT; frequency of TAU sessions was 
allowed to vary and (except in Germany) it was less than MDFT 
 
 
Relevant 
Outcomes 
 
 
Baseline and 
at 3, 6, 9 and 
12 months 
after 
randomization  
 
Primary outcomes:  
- Cannabis use frequency and other substance use disorders 
Measured by TLFB , Personal experience inventory (PEI) for drug problem severity 
 
 
Secondary outcomes:  
- adolescents' psychosocial functioning (symptoms of internalizing and 
externalizing mental and behavioural disorders) 
Measured by Youth Self-report and Child Behaviour Checklist. 
- family functioning (reported in Schaub et al., 2014) 
Measured by Family Environment Scale 
- Treatment satisfaction (planned but not reported) 
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- Retention (at least 3 months in treatment) 
 
 
 
9.2  CHARACTERISTICS OF EXCLUDED STUDIES 
Study and reason for exclusion: 
Becker 2001  Case studies with focus on single mothers.  
Diamond 1999  Focus is on alliances.  
Hogue 1998  Focus is on treatment adherence. Use 20 per cent of participants 
(n=36) from a larger intervention study (n=181); which larger 
intervention study is unclear. 
Hogue 2002 Prevention study 
Hogue 2004 Further analysis of the sample used in Hogue 1998. Therapy 
techniques were measured using observational scales from a 
psychotherapy process instrument developed in a previous study on 
this sample (Hogue et 
al., 1998). 
Liddle 2006 This is a test of a multicomponent, multi-level technology transfer 
intervention developed to train staff. 
  
9.3  RISK OF BIAS OF INDIVIDUAL STUDIES 
 Dennis 2004 
STUDY DESIGN 
QUESTION  
1. How was the intervention 
group(s) formed? 
Random assignment 
2. Give a description of the 
randomization as described by 
the authors 
 
Describe: (pg.199) 600 adolescents and their families 
were recruited and randomized from sequential 
admissions to four treatment sites. It was not logistically 
feasible to implement all five conditions in any one site 
because of the limits of case flow and resources. 
Therefore, adolescents 
were randomly assigned within each site to one of three 
treatment conditions, and the interventions were 
evaluated in two trials 
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3. How was the random sequence 
generated? 
Computer generated list of assignments 
4. How was the randomization done 
in practice? 
(pg.206) Within each site, eligible adolescents were 
assigned to one of the three local conditions using a 
randomly ordered list that was generated by independent 
research staff at the coordinating center using Microsoft 
Excel. To prevent any bias in the assignment process, 
the research staff member was only able to assign an 
adolescent after he or she was determined eligible and 
had completed the intake assessments. 
Assignment logs were kept in a locked file cabinet and 
were never accessible to clinical staff 
 
Dennis et al, 2002: (pg. 25) Within each site, eligible 
adolescents were assigned randomly to one of the three 
local conditions based on their sequence of admission 
using a randomly ordered list of assignments. 
Assignment logs were controlled by the research 
coordinator at each site and routinely reviewed by 
coordinating center staff 
5. What was the unit of 
randomization? 
Stratified on site and blocked within site 
 
Dennis 2004 
RISK OF BIAS 
SEQUENCE GENERATION 
Describe the sequence 
generation: 
See study design 
Was the used sequence generation 
adequate? 
Yes 
 
Sequence generation Final judgment Low 
ALLOCATION CONCEALMENT 
Describe the concealment of 
the allocation: 
See study design 
Was allocation adequately 
concealed regarding participants? 
Meaning that they cannot foresee 
assignment. 
Yes  
Describe the concealment of 
the allocation: 
See study design 
 
Was allocation adequately 
concealed regarding staff? Meaning 
that they cannot foresee 
assignment. 
Yes 
 
Describe the concealment of 
the allocation: 
See study design 
Was allocation adequately 
concealed regarding researchers? 
Meaning that they cannot foresee 
assignment. 
No 
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Allocation concealment Final Judgement Low 
CONFOUNDING not relevant 
BLINDING 
Were outcome assessors 
blinded, and if not do the 
review authors judge that the 
outcome in question was 
unlikely to be influenced by 
lack of blinding? 
Since clinical staff needed to be 
trained in the specific intervention 
they were providing, they could not 
be blind to a participant’s 
assignment. Assignment logs were 
kept in a locked file cabinet and 
were never accessible to clinical 
staff. To prevent bias at follow up, 
tracking and follow up logs were 
maintained separately from 
assignment logs. Unique 
identification numbers were 
assigned to every adolescent 
screened and used by the 
coordinating center to audit the 
randomization process. 
Unclear 
 
Were participants blinded, 
and if not do the review 
authors judge that the 
outcome in question was 
unlikely to be influenced by 
lack of blinding? 
 Not blinded, but unlikely to 
influence 
 
 
Blinding Final judgement Unclear 
INCOMPLETE OUTCOME DATA 
 Do they report drop-outs or lack of 
drop-outs? 
Yes: 5% did not actually receive 
any treatment but were included 
in the analysis 
 Did they perform analysis to 
examine if drop-outs/completers are 
different? (Random or systematic) 
No: One or more follow up 
interviews were completed for all 
except for 3 (out of 600 
randomised) 
Describe how the authors 
deal with missing data: 
Did the authors deal with missing 
data? 
Yes:  Missing items were 
replaced either within scales 
where there were sufficient data 
from the individual or through hot 
deck imputation. See Dennis et 
al 2002, page 26-27 
See description above. Could the imputation method 
chosen influence the outcome? 
No 
Incomplete outcome data Final judgement 1 
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SELECTIVE OUTCOME REPORTING 
Describe incomplete or 
missing outcome reporting: 
Is the study free of selective or 
incomplete outcome reporting?  
 
1 (regarding substance use) 
4 (regarding substance use 
related problems; the protocol 
mentions other outcomes, such 
as family and behavioural 
problems etc. which are not 
reported 
Selective outcome 
reporting 
Final judgement 1 (regarding substance use) 
4 (regarding substance use 
related problems) 
OTHER POTENTIAL THREATS TO VALIDITY 
Describe other sources of 
bias in this study: 
Used block randomization 
stratified on site (random 
allocation rule equivalent to 
one block). Did not specify 
allocation ratio but was 
probably 1:1 and did not 
state that they used block 
randomization and therefore 
did not specify the block size 
(s) 
Is the study free from and/or have 
the study authors adequately dealt 
with other sources of bias? 
3 
 
Other potential threats to 
validity 
Final judgement 3 
 A PRIORI PROTOCOL 
 Did the study follow a priori 
protocol? 
Yes 
Diamond, G., Godley, S. H., 
Liddle, H. A., Sampl, S., Webb, 
C., Tims, F. M. et al. (2002). Five 
outpatient treatment models for 
adolescent marijuana use: a 
description of the Cannabis 
Youth Treatment Interventions. 
Addiction, 97, Suppl-83. 
A priori protocol Final judgment Yes 
A PRIORI ANALYSIS PLAN 
 Did the study follow a priori analysis 
plan? 
Yes 
A priori analysis plan Final judgment Yes 
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 Liddle 2001 
STUDY DESIGN 
QUESTION  
1. How was the intervention group(s) formed? Random assignment 
2. Give a description of the randomization as 
described by the authors 
No information (it only says: Youths 
were randomly assigned to one of 
three treatments: MDFT, MEI, or AGT.) 
3. How was the random sequence generated? Not reported 
4. How was the randomization done in practice? Not reported 
5. What was the unit of randomization? Individual/family 
 
Liddle 2001 
RISK OF BIAS 
SEQUENCE GENERATION 
Describe the sequence 
generation: 
Was the used sequence generation 
adequate? 
Unclear 
Sequence generation Final judgment Unclear 
ALLOCATION CONCEALMENT 
Describe the concealment of 
the allocation: 
 
Was allocation adequately 
concealed regarding participants? 
Meaning that they cannot foresee 
assignment 
Unclear 
Describe the concealment of 
the allocation: 
 
Was allocation adequately 
concealed regarding staff? Meaning 
that they cannot foresee 
assignment. 
Unclear 
Describe the concealment of 
the allocation: 
 
Was allocation adequately 
concealed regarding researchers? 
Meaning that they cannot foresee 
assignment. 
Unclear 
Allocation concealment Final Judgement Unclear 
CONFOUNDING not relevant 
Confounding Final judgement 1; 2; 3; 4; 5; unclear 
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BLINDING 
Were outcome assessors 
blinded, and if not do the 
review authors judge that the 
outcome in question was 
unlikely to be influenced by 
lack of blinding? 
(Regarding drug abuse and school 
performance) 
pg. 666: Information gathered from 
the interviews and urinalyses 
reports were independently 
reviewed by three experienced 
clinician-raters (two master’s level 
and one doctoral level individual). 
These raters, blind to treatment 
condition and assessment phase 
(intake, termination, follow-up), 
reviewed each adolescent’s dossier 
of information about a) type of 
drug(s) used, (b) frequency of use, 
and (c) number and combination of 
different drugs used as determined 
by the three data sources of 
adolescent self-report, parent 
report, and urinalysis results. The 
raters then rated the severity of 
drug use on a Guttman-type 
scale…) 
 
Unclear:  (other outcomes – 
problem behaviour, family 
functioning) 
1 (Regarding drug abuse and 
school performance) 
 
Unclear (regarding other 
outcomes – problem behaviour, 
family functioning) 
 
Were participants blinded, 
and if not do the review 
authors judge that the 
outcome in question was 
unlikely to be influenced by 
lack of blinding? 
 
 
Not blinded, but unlikely to 
influence 
 
Blinding Final judgement 1 (Regarding drug abuse and 
school performance) 
Unclear (regarding other 
outcomes) 
INCOMPLETE OUTCOME DATA 
 Do they report drop-outs or lack of 
drop-outs? 
Yes:  16% refusers and 38% 
dropouts (N even lower for 
family functioning?) 
 Did they perform analysis to 
examine if drop-outs/completers are 
different? (Random or systematic) 
Yes: (both on numbers and 
characteristics) 
Describe how the authors 
deal with missing data: 
Did the authors deal with missing 
data? 
No 
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See description above. Could the imputation method 
chosen influence the outcome 
Not relevant 
 
Incomplete outcome data Final judgement 4 
SELECTIVE OUTCOME REPORTING 
Describe incomplete or 
missing outcome reporting: 
Is the study free of selective or 
incomplete outcome reporting?  
 
1 (regarding substance use) 
2 (Unclear what N is regarding 
family competence and grade 
point average, page 669) 
Selective outcome 
reporting 
Final judgement 1 (regarding substance use) 
2 (regarding family competence 
and grade point average) 
 
OTHER POTENTIAL THREATS TO VALIDITY 
Describe other sources of 
bias in this study: 
The randomization 
procedure is not reported 
Is the study free from and/or have 
the study authors adequately dealt 
with other sources of bias? 
Unclear 
 
Other potential threats to 
validity 
Final judgement Unclear 
 A PRIORI PROTOCOL 
 Did the study follow a priori 
protocol? 
Unclear 
A priori protocol Final judgment Unclear 
A PRIORI ANALYSIS PLAN 
 Did the study follow a priori analysis 
plan? 
Unclear 
A priori analysis plan Final judgment Unclear 
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 Liddle 2008 
STUDY DESIGN 
QUESTION  
1. How was the intervention group(s) 
formed? 
Random assignment 
2. Give a description of the randomization as 
described by the authors 
 
 
 
Describe: After the baseline assessment, we 
used a block randomization procedure. Each 
block consisted of a random ordering of each 
treatment twice (four slots per block, two for 
MDFT and two for CBT for a total of 56 blocks), 
to allocate adolescents randomly to either 
individual CBT (n = 112) or MDFT (n = 112). 
(Pg.103R) 
3. How was the random sequence 
generated? 
Not reported 
4. How was the randomization done in 
practice? 
Not reported 
5. What was the unit of randomization? Blocked 
 
Liddle 2008 
RISK OF BIAS 
SEQUENCE GENERATION 
Describe the sequence 
generation: 
Was the used sequence generation 
adequate? 
Yes 
Sequence generation Final judgment Low 
ALLOCATION CONCEALMENT 
Describe the concealment of 
the allocation: 
 
Was allocation adequately 
concealed regarding participants? 
Meaning that they cannot foresee 
assignment. 
Unclear 
Describe the concealment of 
the allocation: 
 
Was allocation adequately 
concealed regarding staff? Meaning 
that they cannot foresee 
assignment. 
Unclear 
Describe the concealment of 
the allocation: 
 
Was allocation adequately 
concealed regarding researchers? 
Meaning that they cannot foresee 
assignment. 
Unclear 
Allocation concealment Final Judgement Unclear 
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CONFOUNDING not relevant 
Confounding Final judgement 1; 2; 3; 4; 5; unclear 
BLINDING 
Were outcome assessors 
blinded, and if not do the 
review authors judge that the 
outcome in question was 
unlikely to be influenced by 
lack of blinding? 
 Unclear 
 
Were participants blinded, 
and if not do the review 
authors judge that the 
outcome in question was 
unlikely to be influenced by 
lack of blinding? 
 Not blinded, but unlikely to 
influence 
 
Blinding Final judgement Unclear 
INCOMPLETE OUTCOME DATA 
 Do they report drop-outs or lack of 
drop-outs? 
Yes:  (22 out of 112 in each 
treatment) 
 Did they perform analysis to 
examine if drop-outs/completers are 
different? (Random or systematic) 
No 
Describe how the authors 
deal with missing data: 
 
 
 
 
Did the authors deal with missing 
data? 
Yes: (in their analysis (latent 
growth curve model) using FIML 
estimation and the EM 
algorithm, however we did not 
use these estimates. Note the 
missing data level is quite high 
39-46%) 
See description above. Could the imputation method 
chosen influence the outcome? 
 
Unclear: The missing data level 
is quite high and it is hard to 
judge without any sensitivity 
analysis. 
We did not use the estimation 
results. 
Incomplete outcome data Final judgement 4 (regarding substance use, 
no other outcomes reported) 
SELECTIVE OUTCOME REPORTING 
Describe incomplete or 
missing outcome reporting: 
Is the study free of selective or 
incomplete outcome reporting?  
 
1 
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Selective outcome 
reporting 
Final judgement  1 (regarding substance use, 
no other outcomes reported) 
OTHER POTENTIAL THREATS TO VALIDITY 
Describe other sources of 
bias in this study: 
(block size of 4 (and no 
variation in block size) 
carries the risk of being too 
small since researchers and 
staff may crack the code and 
risk selection bias) 
Is the study free from and/or have 
the study authors adequately dealt 
with other sources of bias? 
4 
Other potential threats to 
validity 
Final judgement 4 
 A PRIORI PROTOCOL 
 Did the study follow a priori 
protocol? 
Unclear 
A priori protocol Final judgment Unclear 
A PRIORI ANALYSIS PLAN 
 Did the study follow a priori analysis 
plan? 
Unclear 
A priori analysis plan Final judgment Unclear 
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 Liddle 2009 
STUDY DESIGN 
QUESTION  
1. How was the intervention group(s) 
formed? 
Random assignment 
2. Give a description of the randomization 
as described by the authors 
 
 
 
 
 
Describe: The research coordinator used an urn 
randomization program to ensure equivalence 
(Liddle et al, 2009) 
From Liddle et al, 2004: 
Random assignment was conducted using a 
balancing procedure to ensure equivalence of the 
groups on four key variables: gender, age, ethnicity 
and family income. 
3. How was the random sequence 
generated? 
Computer generated 
4. How was the randomization done in 
practice? 
Details of the urn procedure is not reported  
5. What was the unit of randomization? Individual/family 
 
Liddle 2009 
RISK OF BIAS 
SEQUENCE GENERATION 
Describe the sequence 
generation: 
Was the used sequence generation 
adequate? 
Yes 
 
Sequence generation Final judgment Low 
ALLOCATION CONCEALMENT 
Describe the concealment of 
the allocation: 
 
Was allocation adequately 
concealed regarding participants? 
Meaning that they cannot foresee 
assignment. 
Unclear 
Describe the concealment of 
the allocation: 
 
Was allocation adequately 
concealed regarding staff? Meaning 
that they cannot foresee 
assignment. 
Unclear 
Describe the concealment of 
the allocation: 
Was allocation adequately 
concealed regarding researchers? 
Unclear 
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Meaning that they cannot foresee 
assignment. 
Allocation concealment Final Judgement Unclear 
CONFOUNDING not relevant 
Confounding Final judgement 1; 2; 3; 4; 5; unclear 
BLINDING 
Were outcome assessors 
blinded, and if not do the 
review authors judge that the 
outcome in question was 
unlikely to be influenced by 
lack of blinding? 
 1 (page 16) 
Were participants blinded, 
and if not do the review 
authors judge that the 
outcome in question was 
unlikely to be influenced by 
lack of blinding? 
 Not blinded, but unlikely to 
influence 
Blinding Final judgement 1 
INCOMPLETE OUTCOME DATA 
 Do they report drop-outs or lack of 
drop-outs? 
Yes:   (only 1 drop-out who 
moved out of the area) 
 Did they perform analysis to 
examine if drop-outs/completers are 
different? (Random or systematic) 
Not necessary 
  
Describe how the authors 
deal with missing data: 
In their analysis (latent 
growth curve model) using 
FIML estimation and the 
assumption that data were 
missing at random (MAR). 
However we did not use 
these estimates 
Did the authors deal with missing 
data? 
Yes 
See description above. Could the imputation method 
chosen influence the outcome? 
No:  (only 3% missing data) 
Incomplete outcome data Final judgement 1 
SELECTIVE OUTCOME REPORTING 
Describe incomplete or 
missing outcome reporting: 
Is the study free of selective or 
incomplete outcome reporting?  
1 
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Selective outcome 
reporting 
Final judgement 1 
OTHER POTENTIAL THREATS TO VALIDITY 
Describe other sources of 
bias in this study: 
Urn randomization carries a 
little risk of foreseeing the 
allocation.  Unclear whether 
they used urn randomization 
only to equalize group size 
or to equalize 4 covariates 
as well 
Is the study free from and/or have 
the study authors adequately dealt 
with other sources of bias? 
2  
Other potential threats to 
validity 
Final judgement 2 
 A PRIORI PROTOCOL 
 Did the study follow a priori 
protocol? 
Unclear 
A priori protocol Final judgment Unclear 
A PRIORI ANALYSIS PLAN 
 Did the study follow a priori analysis 
plan? 
Unclear 
A priori analysis plan Final judgment Unclear 
 
 
 
 
 Rigter 2011 
STUDY DESIGN 
QUESTION  
1. How was the intervention group(s) 
formed? 
Random assignment 
 
2. Give a description of the 
randomization as described by the 
authors 
 
 
 
Randomization takes place right after having obtained 
informed consent. We stratified the study sample using 
three (or four in The Netherlands) dichotomous 
variables (age, gender, level of drug abuse, ethnicity). 
In total, across sites and sub-sites, there are 72 strata. 
For each stratum, the database computer generated 50 
independent randomisations. For each site except one 
in France, we have two randomisation arms (MDFT vs. 
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TAU) and we use block randomisation with randomly 
permuted blocks of 2 or 4 cases. 
(Also stratified by site) 
Allocation ratio was 1:1 except for France where it was 
roughly 1:2 (Phan et al 2011) 
3. How was the random sequence 
generated? 
Computer generated 
4. How was the randomization done 
in practice? 
For each stratum, the database computer generated 50 
independent randomisations… (pg.27) 
5. What was the unit of 
randomization? 
Stratified: X (on 3 and 4 variables) 
Blocked: X (blocks of 2 or 4 cases) 
 
Rigter 2011 
RISK OF BIAS 
SEQUENCE GENERATION 
Describe the sequence 
generation: 
Was the used sequence generation 
adequate? 
Yes 
 
Sequence generation Final judgment  
ALLOCATION CONCEALMENT 
Describe the concealment of 
the allocation: 
A researcher enters new 
cases into the database, 
through her site's internet 
location, as soon as informed 
consent has been obtained, 
providing data on the 
stratification variables. Case 
code and randomization 
outcome are given 
automatically and right away, 
enabling the researcher to 
inform the family and to 
schedule appointments with 
the proper therapist without 
delay. 
Was allocation adequately 
concealed regarding participants? 
Meaning that they cannot foresee 
assignment. 
 
Yes:  (they state the allocation 
was concealed on page 27) 
  
Describe the concealment of 
the allocation: 
Was allocation adequately 
concealed regarding staff? Meaning 
that they cannot foresee 
assignment. 
Yes:  (they state the allocation 
was concealed on page 27) 
Describe the concealment of 
the allocation: 
 
Was allocation adequately 
concealed regarding researchers? 
Meaning that they cannot foresee 
assignment. 
Yes:  (they state the allocation 
was concealed on page 27) 
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Allocation concealment Final Judgement Low 
CONFOUNDING not relevant 
Confounding Final judgement 1; 2; 3; 4; 5; unclear 
BLINDING 
Were outcome assessors 
blinded, and if not do the 
review authors judge that the 
outcome in question was 
unlikely to be influenced by 
lack of blinding? 
Given the nature of the 
interventions, local researchers 
cannot be blinded as to the 
treatment delivered. Central 
research staff will be unaware of 
treatment condition when carrying 
out analyses to assess outcomes 
3 
 
Were participants blinded, 
and if not do the review 
authors judge that the 
outcome in question was 
unlikely to be influenced by 
lack of blinding? 
 Not blinded, but unlikely to 
influence 
 
Blinding Final judgement 3 
INCOMPLETE OUTCOME DATA 
There was limited dropout 
from the study after cases 
had been informed about the 
assigned treatment; the 
adolescents/families 
concerned never turned up 
for the first session. We call 
this pre‐treatment dropout. 
Across sites, pre‐treatment 
dropout happened in 3 
MDFT cases (1.4% of total) 
and in 20 TAU cases (8.4% 
of total).  
Do they report drop-outs or lack of 
drop-outs? 
Yes 
 
This difference between 
treatment conditions was 
statistically significant (χ2 [4, 
450] = 11.3, p = 0.001). 
Dropout was caused by the 
youth vanishing out of sight 
by moving away or getting 
detained. One other reason 
was second thoughts among 
family members about the 
desirability of treatment or 
dissatisfaction about the 
assigned treatment (TAU 
rather than MDFT).  
Did they perform analysis to 
examine if drop-outs/completers are 
different? (Random or systematic) 
No (only on numbers of 
pretreatment dropouts) 
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Describe how the authors 
deal with missing data: 
Anyway, all these dropout 
cases were maintained in the 
statistical analyses, 
according to the ‘intention to 
treat’ principle. For repeated 
measures we applied both a 
mixed model for repeated 
measurements and Latent 
Growth Curve Modelling 
(LGM). LGM serves to model 
individual differences in 
change across time. LGM 
has the advantage of 
charting individual change 
trajectories [9] while 
producing unbiased 
estimates when data are 
missing [under the Missing at 
Random assumption, for 
which we checked]. Change 
trajectories were evaluated 
across all assessment 
points. 
Did the authors deal with missing 
data? 
 
There were few missing data. 
Follow‐up assessments completion 
rate was high at all sites for the 12 
months assessment, but more 
variable (the Netherlands) for 
interim follow‐up assessments.  
In INCANT, we achieved an across‐
site 12‐months follow‐up 
completion rate of slightly over 
90%. All sites did well in this 
respect. Interim follow‐up 
completion rates (assessments at 3, 
6 and 9 months) were also good or 
very good, except in the 
Netherlands where these rates 
were in the order of 50%, for 
reasons to be explained in § 3.1. 
(Progress at the Dutch clinical and 
research site was hampered by ill 
fate (death and chronic afflictions of 
collaborators). All this had an 
impact on recruitment success and 
on interim follow-up measurement 
rates) 
Yes: (we did not use these 
estimates) 
 
See description above. Could the imputation method 
chosen influence the outcome? 
Not relevant as we did not use 
the LGM estimates 
Incomplete outcome data Final judgement 3 
SELECTIVE OUTCOME REPORTING 
Describe incomplete or 
missing outcome reporting: 
 
Treatment satisfaction were 
planned but not reported 
Is the study free of selective or 
incomplete outcome reporting?  
 
 
1 (regarding substance use) 
3 (regarding substance related 
problems) 
Selective outcome 
reporting 
Final judgement 1 (regarding substance use) 
3 (regarding substance related 
problems) 
OTHER POTENTIAL THREATS TO VALIDITY 
Describe other sources of 
bias in this study: 
bias in this study: 
(block size of 2 and 4 (3 and 
6) carries the risk of being 
too small since researchers 
Is the study free from and/or have 
the study authors adequately dealt 
with other sources of bias? 
4 
 103      The Campbell Collaboration | www.campbellcollaboration.org 
and staff may crack the code 
and risk selection bias) 
Other potential threats to 
validity 
Final judgement 4 
 A PRIORI PROTOCOL 
 Did the study follow a priori 
protocol? 
Yes:  
 
A priori protocol Final judgment Yes 
A PRIORI ANALYSIS PLAN 
 Did the study follow a priori analysis 
plan? 
Yes:  
 
A priori analysis plan Final judgment Yes 
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10 Additional tables 
10.1  TABLE OF COMPARISONS  
Table 10.1: Comparisons 
Comparison or outcome Studies Participants Statistical method Effect size 
1. Drug use     
    1.1. Drug use problem 
severity 
  
      1.1.1. 6 months post 
intake 
   
             1A 5 830 SMD (random), 95% CI -0.35 [-0.59, -
0.11] 
 
             1B 5 831 SMD (random), 95% CI -0.33 [-0.59, -
0.08] 
 
             2A 5 836 SMD (random), 95% CI -0.31 [-0.53, -
0.10] 
 
             2B 5 837 SMD (random), 95% CI -0.30 [-0.53, -
0.07] 
 
      1.1.2. 12 months post 
intake 
   
             1A 5 826 SMD (random), 95% CI -0.25 [-0.39, -
0.10] 
 
             1B 5 827 SMD (random), 95% CI -0.23 [-0.39, -
0.06] 
 
             2A 5 832 SMD (random), 95% CI -0.27 [-0.43, -
0.11] 
 
             2B 5 833 SMD (random), 95% CI -0.25 [-0.43, -
0.07] 
 
  1.2. Drug use frequency    
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    1.2.1. 6 months post intake    
              A 4 6769 SMD (random), 95% CI -0.24 [-0.43, -
0.06] 
 
              B 4 770 SMD (random), 95% CI -0.25 [-0.40, -
0.11] 
 
     1.2.2. 12 months post 
intake 
   
              A 4 765 SMD (random), 95% CI -0.28 [-0.63, 
0.07] 
 
              B 4 766 SMD (random), 95% CI -0.28 [-0.63, 
0.07] 
 
2. Family functioning    
  2.1. Degree of family 
functioning 
 No total 
  2.2. Positive family 
functioning 
 No total 
  2.3. Negative family 
functioning 
 No total 
3. Education     
  3.1. Grade point average     
    3.1.1. 6 months post-intake    
           1 2 144 SMD (random), 95% CI -0.38 [-1.01, 
0.25] 
 
           2 2 150 SMD (random), 95% CI -0.47 [-0.92, -
0.01] 
 
4. Retention     
  4.1. Completed treatment    
         1A 5 1077 OR (non-event) 
(random), 95% CI 
0.44 [0.21, 0.94] 
 
         1B 5 1077 OR (non-event) 
(random), 95% CI 
0.45 [0.21, 0.95] 
 
         2A 5 1076 OR (non-event) 
(random), 95% CI 
0.48 [0.22, 1.05] 
 
         2B 5 1076 OR (non-event) 
(random), 95% CI 
0.49 [0.22, 1.07] 
 
5. Externalizing symptoms    
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  5.1. YSR    No total 
  5.2. CBCL    No total 
1A: AGT used as comparison in Liddle, 2001 and MET/CBT5 used as comparison in Dennis, 2004  
1B: AGT used as comparison in Liddle, 2001 and ACRA used as comparison in Dennis, 2004  
2A: MEI used as comparison in Liddle, 2001 and MET/CBT5 used as comparison in Dennis, 2004  
2B: MEI used as comparison in Liddle, 2001 and ACRA used as comparison in Dennis, 2004 
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11 Figures 
FLOW CHART DIAGRAM  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
White literature 
SocIndex 202 
Eric 21 
SSCI 392 
SCI 344 
Criminal Justice 
Abstract 
23 
Cinahl 21 
Social Care Online 37 
PsycInfo 145 
Cochrane 52 
Medline 60 
Embase 115 
Bibliotek.dk 345 
Libris 39 
Bibsys 21 
Total   
1817 
  
Grey literature 
Dissertation 58 
Google 350 
Google Scholar 150 
Governmental sites 263 
Multi-disciplinary 
sites 
9 
Subject specific 
sites 
68 
  
Total 898 
Hand search 
Addiction 2037 
Journal of 
Substance Abuse 
Treatment 
776 
Journal of Clinical 
Child and 
Adolescent 
Psychology 
392 
Journal of 
Consulting & 
Clinical Psychology 
527 
Research on Social 
Work Practice 
458 
Snowball 3 
Expert list 4 
  
Total 4196 
392 excluded for being 
duplicates. 
6,519 potential relevant studies (Databases: 1,425, 
grey: 898 and 4,196 from hand search etc.) screened 
for retrieval. 
6,349 articles excluded 
for not fulfilling 
First level screening 
questions 170 papers (121 databases, 46 grey and 3 snowballs) 
retrieved for full text screening. 
5 trials (16 papers) finally met the eligibility criteria and 
where included in the review. 
16 papers met inclusion criteria and were assessed for 
data extraction. 
154 papers were 
excluded for not 
fulfilling the second 
level screening 
questions.  
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SENSITIVITY FIGURES 
 
Figure 11.1 Drug use problem severity 6 months post-intake, sensitivity 
 
 
Figure 11.2 Drug use problem severity 12 months post-intake, sensitivity 
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Figure 11.3 Drug use frequency 6 months post-intake, sensitivity 
 
 
 
 
Figure 11.4 Drug use frequency 12 months post-intake, sensitivity 
 
 
 
 
 
 
 
All studies A
Excluded A: Incomplete data score 4
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All studies B
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12 Differences between review 
and protocol 
In the protocol it was stated in section 3.4.7 that statistically significant 
heterogeneity among primary outcome studies will be been assessed with Chi-
squared (Q) test and I-squared (Higgins, Thompson, Deeks, & Altman, 2003). A 
significant Q (P<.05) and I-squared of at least 50 per cent will be considered as 
statistical heterogeneity. The assessment of heterogeneity has been changed to: 
Heterogeneity among primary outcome studies was assessed with Chi-squared (Q) 
test, and the I-squared, and τ-squared statistics (Higgins, Thompson, Deeks, & 
Altman, 2003). Any interpretation of the Chi-squared test was made cautiously on 
account of its low statistical power. 
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Appendix 
12.1  SEARCH HISTORIES FROM THE BIBLIOGRAPHIC 
DATABASES 
 
 
Criminal Justice Abstract 1968 - current  
June 12, 2011. Ebsco platform.  
 
S1 TI   MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 Famil* ) or (Multi 
n1 dimens* n1 Famil*)  or AB MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* 
n1 Famil* ) or (Multi n1 dimens* n1 Famil*)     17  
Criminal Justice Abstract 1968 - current  
October, 2104. Ebsco platform.  
 
S1 TI   MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 Famil* ) or (Multi 
n1 dimens* n1 Famil*)  or AB MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* 
n1 Famil* ) or (Multi n1 dimens* n1 Famil*)     6 
 
 
ERIC 1966 - current 
June 12, 2011. Ebsco platform.  
  
S1 MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 Famil* ) or (Multi n1 
dimens* n1 Famil*)  or AB MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 
Famil* ) or (Multi n1 dimens* n1 Famil*)    20  
ERIC 1966 - current 
October, 2014. Ebsco platform.  
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S1 MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 Famil* ) or (Multi n1 
dimens* n1 Famil*)  or AB MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 
Famil* ) or (Multi n1 dimens* n1 Famil*)    1  
 
 
SocIndex  1908 - current 
June 12, 2011. Ebsco platform.  
 
 S1 MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 Famil* ) or (Multi n1 
dimens* n1 Famil*)  or AB MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 
Famil* ) or (Multi n1 dimens* n1 Famil*)    185 
SocIndex  1908 - current 
October, 2014. Ebsco platform.  
 
 S1 MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 Famil* ) or (Multi n1 
dimens* n1 Famil*)  or AB MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 
Famil* ) or (Multi n1 dimens* n1 Famil*)    17 
 
 
 
Cinahl 1981 - current  
June 12, 2011. Ebsco platform.  
 
 S1 MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 Famil* ) or (Multi n1 
dimens* n1 Famil*)  or AB MDFT or (Multidimens* n1 Famil*) or (Multi-dimens* n1 
Famil* ) or (Multi n1 dimens* n1 Famil*)     21 
 
 
Medline 1948 - current 
June 12, 2011. Ovid platform.  
 
S1 (MDFT or (Multidimens* adj1 Famil*) or (Multi-dimens* adj1 Famil* ) or (Multi 
adj1 dimens* adj1 Famil*)).af.    43 
Medline 1948 - current 
October,2014. Ovid platform.  
 
S1 (MDFT or (Multidimens* adj1 Famil*) or (Multi-dimens* adj1 Famil* ) or (Multi 
adj1 dimens* adj1 Famil*)).af.    17  
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Embase 1980 - current 
June 12, 2011. Ovid platform.  
 
S1 (MDFT or (Multidimens* adj1 Famil*) or (Multi-dimens* adj1 Famil* ) or (Multi 
adj1 dimens* adj1 Famil*)).   56 
Embase 1980 - current 
October, 2014. Ovid platform.  
 
S1 (MDFT or (Multidimens* adj1 Famil*) or (Multi-dimens* adj1 Famil* ) or (Multi 
adj1 dimens* adj1 Famil*)).   59 
   
   
 
PsycInfo 1806 - current 
June 12, 2011.  Ovid platform.  
 
S1 (MDFT or (Multidimens* adj1 Famil*) or (Multi-dimens* adj1 Famil* ) or (Multi 
adj1 dimens* adj1 Famil*)).af.   111 
PsycInfo 1806 - current 
October, 2014. Ovid platform.  
 
S1 (MDFT or (Multidimens* adj1 Famil*) or (Multi-dimens* adj1 Famil* ) or (Multi 
adj1 dimens* adj1 Famil*)).af.   34 
     
 
 
Social Science Citation Index. 1956 - current 
June 12, 2011.  
  
# 1  Topic=(MDFT or (Multidimens* same Famil*) or (Multi-dimens* same Famil* ) 
or (Multi same dimens* same Famil* ))    333 
Social Science Citation Index. 1956 - current 
October 2014.  
  
# 1  Topic=(MDFT or (Multidimens* same Famil*) or (Multi-dimens* same Famil* ) 
or (Multi same dimens* same Famil* ))    59 
 
 
 
Science Citation Index. 1899 - current 
June 12, 2011.  
 
# 1  Topic=(MDFT or (Multidimens* same Famil*) or (Multi-dimens* same Famil* ) 
or (Multi same dimens* same Famil* ))    303 
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Science Citation Index. 1899 - current 
October, 2014.  
 
# 1  Topic=(MDFT or (Multidimens* same Famil*) or (Multi-dimens* same Famil* ) 
or (Multi same dimens* same Famil* ))    41 
 
 
 
Cochrane 
June 12, 2011 
 
1 (MDFT or (Multidimens* adj1 Famil*) or (Multi-dimens* adj1 Famil*) or (Multi 
adj1 dimens* adj1 Famil*)):ti,ab,kw   39 
Cochrane 
October, 2014 
 
1 (MDFT or (Multidimens* adj1 Famil*) or (Multi-dimens* adj1 Famil*) or (Multi 
adj1 dimens* adj1 Famil*)):ti,ab,kw   14 
    
 
 
Social Care Online 1980 - current 
June 12, 2011 
 
S1 (Multidimens* and famil*) or (Multi-dimens* and famil*) or MDFT 
      2  
Social Care Online 1980 - current 
October, 2014 
 
S1 (Multidimens* and famil*) or (Multi-dimens* and famil*) or MDFT 
      35 
 
 
Bibsys 
June 12, 2011 
 
S1 (Multidimens* and famil*) or (Multi-dimens* and famil*) or MDFT 
      10 
Bibsys 
October, 2014 
 
S1 (Multidimens* and famil*) or (Multi-dimens* and famil*) or MDFT 
      11 
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Libris 
June 12, 2011 
 
S1 (Multidimens* and famil*) or (Multi-dimens* and famil*) or MDFT 
      12 
Libris 
October, 2014. 
 
S1 (Multidimens* and famil*) or (Multi-dimens* and famil*) or MDFT 
      27 
 
Bibliotek.dk 
June 12, 2011 
 
S1 (Multidimens? and famil?) or (Multi-dimens? and famil?) or MDFT  
      301 
Bibliotek.dk 
October. 2014. 
 
S1 (Multidimens? and famil?) or (Multi-dimens? and famil?) or MDFT  
      44 
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12.2  CODE BOOK FOR DATA EXTRACTION 
Author Study x 
Year  
Country  
Is this study about a MDFT intervention 
evaluation? 
 
Are the participants 11 - 21 years of age?  
Are the participants in outpatient drug treatment 
for illicit non-opioid drug use? 
 
Is the report a  
…P=Primary study  
RE=Review  (Effect/meta-analysis) 
RD=Review (Descriptive)  
D=Descriptive 
T=Theoretical paper 
O=Other 
 
Is the study an RCT with a control group?  
Is the study a non-randomized controlled study 
with a control group? 
 
Is the study..  
Notes  
State reason (if necessary) for excluded or 
uncertain. 
 
If lack of info., state question(s) to be sent to 
study authors. 
 
Objectives of the study  
How many separate sites/facilities are included in 
the study? 
 
If an RCT, was random assignment performed in 
the same way in all sites? 
 
List all the treatment groups in the study  
Were there any implementation differences 
between groups? 
 
Location of treatment  
Location details  
If multiple sites, were there any implementation 
differences between sites? 
 
Was participant inclusion criteria mentioned?  
If yes describe.  
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Was participant exclusion criteria mentioned?  
If yes describe.  
Describe how the participants were referred to 
the intervention. 
 
Is the intervention mandated?  
If yes by whom and how many?  
Gender (e.g. % male)  
Age (details on age as presented in the study)  
Race/ ethnicity  
Socioeconomic status  
Family composition  
Other characteristics  
Specify the main drug  
Provide short description of the distribution of 
drug use 
 
List/describe history/severity of drug use  
List any comorbid condition  
Report total no. of participants randomized  
 
Intervention   
Name the intervention  
How is the intervention delivered?   
If Family, Other or Combination, describe the way it 
is delivered 
 
Describe any practical circumstances relevant to the 
intervention 
 
If deviation from manual, describe/list the 
components given in the intervention   
 
Describe any co-interventions given with the 
intervention 
 
Frequency of the intervention   
Intensity  
Duration of the intervention    
Who delivered the intervention?  
List program delivers qualifications.  
List program delivers characteristics.  
Describe methods used to ensure adherence to the 
intervention (specific to the intervention) 
 
What did the investigators do to check/measure 
treatment fidelity? 
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Other important information  
 
Control group   
Name the control/comparison condition intervention  
How is the control intervention delivered?   
If Family, Other or Combination, describe the way it 
is delivered 
 
Describe any practical circumstances relevant to the 
intervention 
 
If deviation from manual, describe/list the 
components given in the intervention   
 
Describe any co-interventions given with the 
comparison intervention 
 
Frequency of the intervention   
Intensity  
Duration of the intervention    
Who delivered the intervention?  
List program delivers qualifications  
List program delivers characteristics  
Describe methods used to ensure adherence to the 
intervention 
 
What did the investigators do to check/measure 
treatment fidelity? 
 
Did they measure session attendance?  
Other important information  
 
  
Baseline time - describe how baseline is defined  
End of treatment (from baseline time) to…  
...1st follow-up  
…2nd follow-up  
…3rd follow-up  
…Other  
Author's main conclusion  
Limitations of the study, as reported by the study 
authors 
 
Researcher’s affiliation with program (if any)  
Your own concerns and notes   
Question(s) for review authors   
 
OUTCOMES    
Outcome measurement    
What does it measure?  
Reliability & Validity  
Outcome measurement format (continous or binary)   
Direction   
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Mode  
If other, describe   
Source   
If other, describe   
NOTES   
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N’s INTERVENTION1* Comparison 1* Comparsion 2 TOTAL Pg. # & NOTES 
etc on drops 
outs (& reason if 
given)   and 
missing data  
Drop out n's - %  
in intervention 
group  
Drop out n's -   %  
in control   group  
Referred to study or recruited                
Consented               
Completed base line measures               
Randomly assigned               
Or non randomly allocated               
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Started treatment               
Completed treatment               
Completed  first measure after 
baseline 
              
Completed 1st follow up               
Completed 2nd follow up(add rows 
for as required for additional 
follow ups) 
              
*Add columns as required        
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12.3  ASSESSMENT OF RISK OF BIAS IN INCLUDED STUDIES: 
GUIDELINES 
 
Risk of bias table 
 
Item Judgmental Description (quote from 
paper, or describe key 
information) 
1. Sequence generation 
  
2. Allocation concealment 
  
3. Confoundingb,       
  
4. Blinding?b                   
  
5. Incomplete outcome data 
addressed?b 
  
6. Free of selective reporting?b 
  
7. Free of other bias? 
  
8. A priori protocol?d 
  
9. A priori analysis plan?e 
  
 
a Some items on low/high risk/unclear scale (double-line border), some on 5 
point scale/unclear (single line border), some on yes/no/unclear scale (dashed 
border). For all items, record “unclear” if inadequate reporting prevents a 
judgment being made. 
b For each outcome in the study.  
c This item is based on list of confounders considered important at the outset 
and defined in the protocol for the review (assessment against worksheet).  
d Did the researchers write a protocol defining the study population, intervention 
and comparator, primary and other outcomes, data collection methods, etc. in 
advance of starting the study? 
e Did the researchers have an analysis plan defining the primary and other 
outcomes, statistical methods, subgroup analyses, etc. in advance of starting 
the study? 
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Risk of bias tool 
 
Studies for which RoB tool is intended 
The risk of bias model is developed by Prof. Barnaby Reeves in association with the 
Cochrane Non-Randomized Studies Methods Group.15 This model, an extension of 
the Cochrane Collaboration’s risk of bias tool, covers both risk of bias in randomized 
controlled trials (RCTs and QRCTs), but also risk of bias in non-randomized studies 
(in this case non-randomized controlled trials NRCTs).   
The point of departure for the risk of bias model is the Cochrane Handbook for 
Systematic Reviews of interventions (Higgins & Green, 2008). The existing 
Cochrane risk of bias tool needs elaboration when assessing non-randomized studies 
because, for non-randomized studies, particular attention should be paid to 
selection bias / risk of confounding.   
 
 
Assessment of risk of bias 
Issues when using modified RoB tool to assess included non-randomized studies: 
 Use existing principle: score judgment and provide information (preferably 
direct quote) to support judgment 
 Additional item on confounding used for RCTs and NRCTs. 
 5-point scale for some items (distinguish “unclear” from intermediate risk of 
bias). 
 Keep in mind the general philosophy – assessment is not about whether 
researchers could have done better but about risk of bias; the assessment tool 
must be used in a standard way whatever the difficulty / circumstances of 
investigating the research question of interest and whatever the study design 
used. 
 Anchors: “1/No/low risk” of bias should correspond to a high quality RCT. 
“5/high risk” of bias should correspond to a risk of bias that means the 
findings should not be considered (too risky, too much bias, more likely to 
mislead than inform) 
 
1. Sequence generation 
 Low/high/unclear RoB item 
 Always high RoB (not random) for a non-randomized study 
 Might argue that this item redundant for NRS since always high – but 
important to include in RoB table (‘level playing field’ argument) 
 
2. Allocation concealment 
 Low/high/unclear RoB item 
 Potentially low RoB for a non-randomized study, e.g. quasi-randomized (so 
high RoB to sequence generation) but concealed (reviewer judges that the 
people making decisions about including participants didn’t know how 
allocation was being done, e.g. odd/even date of birth/hospital number) 
 
3. RoB from confounding ( assess for each outcome) 
 Assumes a pre-specified list of potential confounders defined in the protocol 
 Low(1) / 2 / 3 / 4 / high(5) / unclear RoB item 
 Judgment needs to factor in: 
                                                        
15 This risk of bias model was introduced by Prof. Reeves at a workshop on risk of bias in non-
randomized studies at SFI Campbell, February 2011. The model is a further development of work 
carried out in the Cochrane Non-Randomized Studies Method Group (NRSMG). 
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o  proportion of confounders (from pre-specified list) that were 
considered 
o whether most important confounders (from pre-specified list) were 
considered 
o resolution/precision with which confounders were measured 
o extent of imbalance between groups at baseline 
o care with which adjustment was done (typically a judgment about the 
statistical modeling carried out by authors) 
 Low RoB requires that all important confounders are balanced at baseline 
(not primarily/not only a statistical judgment OR measured ‘well’ and 
‘carefully’ controlled for in the analysis. 
 
Assess against pre-specified worksheet. Reviewers will make a RoB judgment about 
each factor first and then ‘eyeball’ these for the judgment RoB table. 
 
4. RoB from lack of blinding (assess for each outcome, as per existing RoB tool) 
 Low(1) / 2 / 3 / 4 / high(5) / unclear RoB item 
 Judgment needs to factor in: 
o nature of outcome (subjective / objective; source of information) 
o who was / was not blinded and the risk that those who were not 
blinded could introduce performance or detection bias 
o see Ch.8 
 
5. RoB from incomplete outcome data (assess for each outcome, as per existing RoB 
tool) 
 Low(1) / 2 / 3 / 4 / high(5) / unclear RoB item 
 Judgment needs to factor in: 
o reasons for missing data 
o whether amount of missing data balanced across groups, with similar 
reasons 
o see Ch.8 
 
6. RoB from selective reporting (assess for each outcome, NB different to existing 
Ch.8 recommendation) 
 Low(1) / 2 / 3 / 4 / high(5) /unclear RoB item 
 Judgment needs to factor in: 
o existing RoB guidance on selective outcome reporting 
o see Ch.8 
o also, extent to which analyses (and potentially other choices) could 
have been manipulated to bias the findings reported, e.g. choice of 
method of model fitting, potential confounders considered / included    
o look for evidence that there was a protocol in advance of doing any 
analysis / obtaining the data (difficult unless explicitly reported); 
NRS very different from RCTs. RCTs must have a protocol in advance 
of starting to recruit (for REC/IRB/other regulatory approval); NRS 
need not (especially older studies) 
o Hence, separate yes/no items asking reviewers whether they think 
the researchers had a pre-specified protocol and analysis plan. 
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Confounding Worksheet 
Assessment of how researchers dealt with confounding  
Method for identifying relevant confounders described by researchers:                          yes 
                                                                                                                                                            no                                                                                                                            
If yes, describe the method used: 
 
 
Relevant confounders described:                                                                                               yes 
                                                                                                                                                            no 
List confounders described on next page 
 
Method used for controlling for confounding 
At design stage (e.g. matching, regression discontinuity, instrument variable):  
………………………………………………..      
………………………………………………..  
………………………………………………..            
 
At analysis stage (e.g. stratification, multivariate regression, difference-indifference):    
………………………………………………..      
………………………………………………..  
………………………………………………..            
 
 
Describe confounders controlled for below 
 
 
Confounders described by researchers 
Tick (yes[0]/no[1] judgment) if confounder considered by the researchers [Cons’d?] 
Score (1[good precision] to 5[poor precision]) precision with which confounder measured 
Score (1[balanced] to 5[major imbalance]) imbalance between groups 
Score (1[very careful] to 5[not at all careful]) care with which adjustment for confounder was carried 
out 
 
Confounder Considered Precision Imbalance Adjustment 
Gender     
Age     
History of drug use      
Other      
Other:     
Other:     
 
 
